@NP	Transplantation of Schwann Cells	1
@NP	Transplantation	1
@NP	Schwann Cells	20
@NP	Olfactory Ensheathing Glia after Spinal Cord Injury	38
@NP	Olfactory Ensheathing Glia	38
@NP	Spinal Cord Injury	71
@NP	Does Pretreatment with Methylprednisolone and Interleukin-10	91
@NP	Does Pretreatment	91
@NP	Methylprednisolone and Interleukin-10	114
@NP	Recovery	160
@NP	DAMIEN DANIEL PEARSE	171
@NP	ALEXANDER EDUARDO MARCILLO , MARTIN OUDEGA ,2	193
@NP	MICHAEL PAUL LYNCH , PATRICK MCGHEE WOOD ,2 and MARY BARTLETT	237
@NP	MICHAEL PAUL LYNCH	237
@NP	PATRICK MCGHEE WOOD ,2	257
@NP	MARY BARTLETT	283
@NP	BUNGE1 ,2	297
@NP	ABSTRACT Methylprednisolone -LRB- MP -RRB- and interleukin-10 -LRB- IL-10 -RRB-	307
@NP	ABSTRACT Methylprednisolone -LRB- MP -RRB-	307
@NP	ABSTRACT Methylprednisolone	307
@NP	MP	336
@NP	interleukin-10 -LRB- IL-10 -RRB-	344
@NP	interleukin-10	344
@NP	IL-10	360
@NP	tissue protective	371
@NP	spinal cord injury -LRB- SCI -RRB-	403
@NP	spinal cord injury	403
@NP	SCI	423
@NP	their combination	429
@NP	additive protection -LRB- Takami et al. , 2002a -RRB-	454
@NP	additive protection	454
@NP	Takami	475
@NP	et al. , 2002a	482
@NP	et al.	482
@NP	2002a	490
@NP	Our study	498
@NP	acute administration	520
@NP	MP	544
@NP	30 mg/kg i.v. at 5 min , and 2 and 4 h after injury	548
@NP	30 mg/kg i.v.	548
@NP	5 min	565
@NP	2 and 4 h after injury	576
@NP	2 and 4 h	576
@NP	injury	592
@NP	IL-10	604
@NP	30 min	627
@NP	injury	640
@NP	the efficacy of Schwann cell -LRB- SC -RRB-	658
@NP	the efficacy	658
@NP	Schwann cell -LRB- SC -RRB-	674
@NP	Schwann cell	674
@NP	SC	688
@NP	SC plus olfactory ensheathing glia -LRB- SC/OEG -RRB- grafts	695
@NP	SC	695
@NP	olfactory ensheathing glia -LRB- SC/OEG -RRB- grafts	703
@NP	rat thoracic cord 1 week	764
@NP	rat thoracic cord	764
@NP	1 week	782
@NP	contusive injury	795
@NP	Efficacy	813
@NP	histology , anterograde and retrograde tracing	840
@NP	histology	840
@NP	anterograde	851
@NP	retrograde tracing	867
@NP	retrograde	867
@NP	immunohistochemistry for gliosis and specific nerve fibers	887
@NP	immunohistochemistry	887
@NP	gliosis and specific nerve fibers	912
@NP	several behavioral tests	951
@NP	Administration of MP/IL - 10 or SC or SC/OEG transplantation	977
@NP	Administration	977
@NP	MP/IL - 10 or SC or SC/OEG transplantation	995
@NP	MP/IL	995
@NP	10 or SC or SC/OEG transplantation	1002
@NP	10	1002
@NP	SC or SC/OEG transplantation	1008
@NP	the total volume of a 9-mm segment of cord	1061
@NP	the total volume	1061
@NP	a 9-mm segment of cord	1081
@NP	a 9-mm segment	1081
@NP	cord	1099
@NP	the injury site	1117
@NP	12 weeks	1136
@NP	The combination of either SC or SC/OEG transplantation with MP/IL -10	1146
@NP	The combination	1146
@NP	either SC or SC/OEG transplantation	1165
@NP	SC	1172
@NP	SC/OEG transplantation	1178
@NP	MP/IL -10	1206
@NP	cavitation	1242
@NP	The individual treatments	1254
@NP	the volume of normal-appearing tissue	1308
@NP	the volume	1308
@NP	normal-appearing tissue	1322
@NP	injury-only controls	1358
@NP	significant decreases in the volume of normal-appearing tissue	1389
@NP	significant decreases	1389
@NP	the volume of normal-appearing tissue	1414
@NP	the volume	1414
@NP	normal-appearing tissue	1428
@NP	MP/IL -10 and cell grafts	1467
@NP	MP/IL -10	1467
@NP	cell grafts	1480
@NP	MP/IL -10	1518
@NP	SC/OEG grafts	1534
@NP	serotonergic fiber growth	1576
@NP	the graft	1607
@NP	more reticulospinal fibers caudal to the graft	1628
@NP	more reticulospinal fibers	1628
@NP	the graft	1665
@NP	combination with MP/IL -10	1676
@NP	combination	1676
@NP	MP/IL -10	1693
@NP	further increase fiber number	1710
@NP	Only the combination of MP/IL - 10 with SC/OEG transplants	1741
@NP	Only the combination	1741
@NP	MP/IL - 10 with SC/OEG transplants	1765
@NP	MP/IL	1765
@NP	10 with SC/OEG transplants	1772
@NP	10	1772
@NP	SC/OEG transplants	1780
@NP	gross locomotor performance -LRB- BBB scores -RRB-	1822
@NP	gross locomotor performance	1822
@NP	BBB scores	1851
@NP	injury-only controls	1868
@NP	MP/IL -10 given prior to SC-only transplants	1890
@NP	MP/IL -10	1890
@NP	SC-only transplants	1914
@NP	behavioral outcome	1953
@NP	beneficial effects of MP/IL -10	1981
@NP	beneficial effects	1981
@NP	MP/IL -10	2003
@NP	cell transplantation	2056
@NP	we	2078
@NP	tissue protective agents	2108
@NP	the milieu of the injured spinal cord	2147
@NP	the milieu	2147
@NP	the injured spinal cord	2161
@NP	the benefit or detriment of later transplanted cells	2188
@NP	the benefit or detriment	2188
@NP	later transplanted cells	2216
@NP	neuroprotectants	2257
@NP	the time of cell grafting	2304
@NP	the time	2304
@NP	cell grafting	2316
@NP	less invasive transplantation techniques	2333
@NP	damage	2393
@NP	tissue spared by an earlier protection strategy	2403
@NP	tissue	2403
@NP	an earlier protection strategy	2420
@NP	INTRODUCTION TRAUMA TO THE SPINAL CORD	2453
@NP	INTRODUCTION TRAUMA TO	2453
@NP	INTRODUCTION TRAUMA	2453
@NP	THE SPINAL CORD	2476
@NP	an immediate mechanical and irreversible disruption	2506
@NP	cellular and axonal integrity	2561
@NP	a later initiation of a cascade of processes	2595
@NP	a later initiation	2595
@NP	a cascade of processes	2617
@NP	a cascade	2617
@NP	processes	2630
@NP	progressive neural damage	2656
@NP	Òsecondary injuryÓ	2690
@NP	Schwab and Bartholdi , 1996 ; Amar and Levy , 1999	2710
@NP	Schwab and Bartholdi	2710
@NP	1996 ; Amar and Levy	2732
@NP	1996	2732
@NP	Amar and Levy	2738
@NP	1999	2753
@NP	Therapies for spinal cord injury	2760
@NP	Therapies	2760
@NP	spinal cord injury	2774
@NP	two directions	2826
@NP	the use	2846
@NP	expansion	2886
@NP	the secondary injury and -LRB- ii -RRB- the employment of regenerative	2899
@NP	the secondary injury	2899
@NP	ii	2925
@NP	the employment of regenerative	2929
@NP	the employment	2929
@NP	reparative strategies	2961
@NP	tissue	3010
@NP	lost connections and function	3031
@NP	Methylprednisolone -LRB- MP -RRB- , an anti-inflammatory glucocorticosteroid ,	3062
@NP	Methylprednisolone -LRB- MP -RRB-	3062
@NP	Methylprednisolone	3062
@NP	MP	3082
@NP	an anti-inflammatory glucocorticosteroid	3087
@NP	one such protective drug	3132
@NP	its way	3171
@NP	the clinic , recommended for use acutely following SCI in the United States	3184
@NP	the clinic	3184
@NP	use acutely following SCI in the United States	3212
@NP	use	3212
@NP	SCI in the United States	3234
@NP	SCI	3234
@NP	the United States	3241
@NP	It	3260
@NP	the degree of behavioral deficits	3303
@NP	the degree	3303
@NP	behavioral deficits	3317
@NP	experimental models	3340
@NP	SCI -LRB- Braughler et al. , 1987 ; Behrmann et al. , 1994 -RRB-	3363
@NP	SCI	3363
@NP	Braughler	3368
@NP	et al. , 1987 ; Behrmann et al. , 1994	3378
@NP	et al.	3378
@NP	1987 ; Behrmann et al.	3386
@NP	1987	3386
@NP	Behrmann et al.	3392
@NP	Behrmann	3392
@NP	et al.	3401
@NP	1994	3409
@NP	the mechanism by which MP is protective	3425
@NP	the mechanism	3425
@NP	MP	3448
@NP	an open question	3474
@NP	some debate	3497
@NP	its long-term benefit	3520
@NP	the clinical setting	3545
@NP	Nesathurai , 1998 ; Hurlbert , 2000 ; Short et al. , 2000	3567
@NP	Nesathurai	3567
@NP	1998 ; Hurlbert , 2000 ; Short et al.	3579
@NP	1998	3579
@NP	Hurlbert , 2000 ; Short et al.	3585
@NP	Hurlbert , 2000	3585
@NP	Hurlbert	3585
@NP	2000	3595
@NP	Short et al.	3601
@NP	Short	3601
@NP	et al.	3607
@NP	2000	3615
@NP	rat models of SCI	3625
@NP	rat models	3625
@NP	SCI	3639
@NP	MP administration	3644
@NP	the accumulation of immune cells	3673
@NP	the accumulation	3673
@NP	immune cells	3693
@NP	the lesion site -LRB- Bartholdi and Schwab , 1995 ; Oudega et al. , 1999 -RRB-	3713
@NP	the lesion site	3713
@NP	Bartholdi and Schwab , 1995 ; Oudega et al. , 1999	3730
@NP	Bartholdi and Schwab	3730
@NP	1995 ; Oudega et al.	3752
@NP	1995	3752
@NP	Oudega et al.	3758
@NP	Oudega	3758
@NP	et al.	3765
@NP	1999	3773
@NP	tissue loss and axonal dieback	3791
@NP	Chen	3823
@NP	et al. , 1996 ; Oudega et al. , 1999	3828
@NP	et al.	3828
@NP	1996 ; Oudega et al.	3836
@NP	1996	3836
@NP	Oudega et al.	3842
@NP	Oudega	3842
@NP	et al.	3849
@NP	1999	3857
@NP	Interleukin-10 -LRB- IL-10 -RRB-	3864
@NP	Interleukin-10	3864
@NP	IL-10	3880
@NP	another potent anti-inflammatory molecule	3890
@NP	tissue loss	3960
@NP	several models	3975
@NP	CNS injury	3993
@NP	Knoblach and Faden , 1998 ; Brewer et al. , 1999 ; Plunkett et al. , 2001	4005
@NP	Knoblach and Faden	4005
@NP	1998 ; Brewer et al. , 1999 ; Plunkett et al.	4025
@NP	1998	4025
@NP	Brewer et al. , 1999 ; Plunkett et al.	4031
@NP	Brewer	4031
@NP	et al. , 1999 ; Plunkett et al.	4038
@NP	et al. , 1999	4038
@NP	et al.	4038
@NP	1999	4046
@NP	Plunkett et al.	4052
@NP	Plunkett	4052
@NP	et al.	4061
@NP	2001	4069
@NP	The systemic administration of IL-10	4076
@NP	The systemic administration	4076
@NP	IL-10	4107
@NP	SCI	4127
@NP	tissue loss	4182
@NP	open-field locomotion -LRB- Bethea et al. , 1999 -RRB-	4206
@NP	open-field locomotion	4206
@NP	Bethea	4229
@NP	et al. , 1999	4236
@NP	et al.	4236
@NP	1999	4244
@NP	We	4251
@NP	MP and IL-10	4300
@NP	spinal cord contusion	4319
@NP	there	4342
@NP	significant enhancement	4351
@NP	tissue sparing	4378
@NP	either compound administered alone	4398
@NP	either compound	4398
@NP	Takami	4434
@NP	et al. , 2002a	4441
@NP	et al.	4441
@NP	2002a	4449
@NP	the acute administration	4466
@NP	MP	4494
@NP	Oudega	4498
@NP	et al. , 1999 ; Takami et al. , 2002a	4505
@NP	et al.	4505
@NP	1999 ; Takami et al.	4513
@NP	1999	4513
@NP	Takami et al.	4519
@NP	Takami	4519
@NP	et al.	4526
@NP	2002a	4534
@NP	IL-10	4545
@NP	Bethea	4552
@NP	et al. , 1999 ; Takami et al. , 2002a	4559
@NP	et al.	4559
@NP	1999 ; Takami et al.	4567
@NP	1999	4567
@NP	Takami et al.	4573
@NP	Takami	4573
@NP	et al.	4580
@NP	2002a	4588
@NP	injury-induced tissue damage	4603
@NP	SCI	4638
@NP	severe	4643
@NP	functional deficits persist	4650
@NP	functional deficits	4650
@NP	Takami et al. , 2002a	4679
@NP	Takami	4679
@NP	et al.	4686
@NP	2002a	4694
@NP	functional restitution	4722
@NP	additional repair strategies	4746
@NP	lost cells	4803
@NP	regeneration of damaged axons for re-connection to their appropriate targets	4829
@NP	regeneration	4829
@NP	damaged axons for re-connection to their appropriate targets	4845
@NP	damaged axons	4845
@NP	re-connection to their appropriate targets	4863
@NP	re-connection	4863
@NP	their appropriate targets	4880
@NP	Cellular grafting strategies with various cell types	4907
@NP	Cellular grafting strategies	4907
@NP	various cell types	4941
@NP	improvements in behavioral recovery	5000
@NP	improvements	5000
@NP	behavioral recovery	5016
@NP	SCI	5042
@NP	Li	5047
@NP	et al. , 1997	5050
@NP	et al.	5050
@NP	1997	5058
@NP	Liu et al. , 1999	5064
@NP	Liu	5064
@NP	et al. , 1999	5068
@NP	et al.	5068
@NP	1999	5076
@NP	McDonald et al. , 1999	5082
@NP	McDonald	5082
@NP	et al. , 1999	5091
@NP	et al.	5091
@NP	1999	5099
@NP	Ram -- n-Cueto et al. , 2000	5105
@NP	Ram	5105
@NP	n-Cueto et al. , 2000	5109
@NP	et al. , 2000	5117
@NP	et al.	5117
@NP	2000	5125
@NP	Takami et al. , 2002b	5131
@NP	Takami	5131
@NP	et al. , 2002b	5138
@NP	et al.	5138
@NP	2002b	5146
@NP	A well-studied and frequently employed cell type for SCI repair	5154
@NP	A well-studied and frequently employed cell type	5154
@NP	SCI repair	5207
@NP	the Schwann cell -LRB- SC -RRB-	5221
@NP	the Schwann cell	5221
@NP	SC	5239
@NP	a myelinating glial cell	5244
@NP	the peripheral nervous system	5272
@NP	regeneration	5316
@NP	propriospinal neurons	5332
@NP	Xu et al. , 1995a , 1997 , 1999 ; Guest et al. , 1997	5355
@NP	Xu	5355
@NP	et al. , 1995a , 1997 , 1999 ; Guest et al. , 1997	5358
@NP	et al.	5358
@NP	1995a	5366
@NP	1997	5373
@NP	1999 ; Guest et al.	5379
@NP	1999	5379
@NP	Guest et al.	5385
@NP	Guest	5385
@NP	et al.	5391
@NP	1997	5399
@NP	brainstem neurons	5409
@NP	the presence of neurotrophic factors	5431
@NP	the presence	5431
@NP	neurotrophic factors	5447
@NP	Xu et al. , 1995b ; Menei et al. , 1998 ; Bamber et al. , 2001	5470
@NP	Xu	5470
@NP	et al. , 1995b ; Menei et al. , 1998 ; Bamber et al. , 2001	5473
@NP	et al. , 1995b	5473
@NP	et al.	5473
@NP	1995b	5481
@NP	Menei et al. , 1998	5488
@NP	Menei	5488
@NP	et al. , 1998	5494
@NP	et al.	5494
@NP	1998	5502
@NP	Bamber et al. , 2001	5508
@NP	Bamber	5508
@NP	et al. , 2001	5515
@NP	et al.	5515
@NP	2001	5523
@NP	the injured spinal cord	5549
@NP	The olfactory ensheathing glial cell -LRB- OEG -RRB-	5574
@NP	The olfactory ensheathing glial cell	5574
@NP	OEG	5612
@NP	another cell type	5620
@NP	promise	5653
@NP	repair	5664
@NP	the injured spinal cord	5674
@NP	Li	5699
@NP	et al.	5702
@NP	1997 , 1998 ; Ram -- n-Cueto et al. , 1998 , 2000 ; Takami et al.	5710
@NP	1997 , 1998	5710
@NP	1997	5710
@NP	1998	5716
@NP	Ram -- n-Cueto et al. , 1998 , 2000	5722
@NP	Ram -- n-Cueto et al. , 1998	5722
@NP	Ram	5722
@NP	et al. , 1998	5734
@NP	et al.	5734
@NP	1998	5742
@NP	2000	5748
@NP	Takami et al.	5754
@NP	Takami	5754
@NP	et al.	5761
@NP	2002b	5769
@NP	particular an ability	5791
@NP	long-tract regeneration and behavioral recovery	5827
@NP	a complete transection model -LRB- Ram -- n-Cueto et al. , 2000 -RRB-	5878
@NP	a complete transection model	5878
@NP	Ram	5908
@NP	n-Cueto et al. , 2000	5912
@NP	n-Cueto	5912
@NP	et al.	5920
@NP	2000	5928
@NP	a SC bridge	5958
@NP	OEG implanted into the host spinal cord stumps after complete transection	5975
@NP	OEG	5975
@NP	the host spinal cord stumps	5994
@NP	complete transection	6028
@NP	regeneration	6058
@NP	axons	6104
@NP	the caudal and rostral cord , respectively	6115
@NP	the caudal and rostral cord	6115
@NP	Ram	6158
@NP	n-Cueto et al. , 1998	6162
@NP	n-Cueto	6162
@NP	et al.	6170
@NP	1998	6178
@NP	the current study	6188
@NP	we	6207
@NP	combined MP and IL-10	6222
@NP	the efficacy of rat SC or SC/OEG grafts	6259
@NP	the efficacy	6259
@NP	rat SC or SC/OEG grafts	6275
@NP	behavioral recovery following transplantation	6310
@NP	1 week after moderate contusive injury	6359
@NP	1 week	6359
@NP	moderate contusive injury	6372
@NP	a model	6399
@NP	a common form of human SCI	6420
@NP	a common form	6420
@NP	human SCI	6437
@NP	Bunge	6448
@NP	et al. , 1997 ; Kakulas , 1999	6454
@NP	et al.	6454
@NP	1997 ; Kakulas	6462
@NP	1997	6462
@NP	Kakulas	6468
@NP	1999	6477
@NP	MATERIALS AND METHODS Cultures Schwann cells .	6485
@NP	MATERIALS AND METHODS	6485
@NP	MATERIALS	6485
@NP	METHODS	6499
@NP	Cultures Schwann cells	6507
@NP	Cultures	6507
@NP	Schwann cells	6516
@NP	SCs	6531
@NP	sciatic nerves	6554
@NP	adult female Fischer rats -LRB- Harlan Co , Indianapolis , IN -RRB-	6572
@NP	adult female Fischer rats	6572
@NP	Harlan Co , Indianapolis	6599
@NP	Harlan Co	6599
@NP	Indianapolis	6610
@NP	Morrissey	6653
@NP	et al. , 1991	6663
@NP	et al.	6663
@NP	1991	6671
@NP	the nerves	6687
@NP	culture dishes	6724
@NP	DMEM/10 % heat inactivated fetal bovine serum -LRB- FBS -RRB- without mitogens	6742
@NP	DMEM/10 %	6742
@NP	heat	6751
@NP	fetal bovine serum -LRB- FBS -RRB-	6768
@NP	fetal bovine serum	6768
@NP	FBS	6788
@NP	mitogens	6801
@NP	Two weeks later	6811
@NP	outward migration of fibroblasts	6834
@NP	outward migration	6834
@NP	fibroblasts	6855
@NP	the explants	6868
@NP	new dishes where they were enzymatically dissociated	6901
@NP	new dishes	6901
@NP	they	6918
@NP	then re-plated in DMEM/10 % FBS	6958
@NP	DMEM/10 %	6976
@NP	three mitogens	7007
@NP	bovine pituitary extract	7023
@NP	2 mg/mL	7049
@NP	Invitrogen Corporation	7058
@NP	Carlsbad , CA	7082
@NP	forskolin -LRB- 0.8 µg/mL -RRB-	7097
@NP	forskolin	7097
@NP	0.8 µg/mL	7108
@NP	heregulin -LRB- 2.5 nM , Genentech , San Francisco , CA -RRB-	7124
@NP	heregulin	7124
@NP	2.5 nM , Genentech , San Francisco , CA	7135
@NP	2.5 nM	7135
@NP	Genentech	7143
@NP	San Francisco	7154
@NP	CA	7169
@NP	Meijs	7174
@NP	et al. , 2004	7180
@NP	et al.	7180
@NP	2004	7188
@NP	Cells	7195
@NP	confluency	7215
@NP	new dishes	7242
@NP	three times	7253
@NP	Their purity for grafting	7266
@NP	Their purity	7266
@NP	grafting	7283
@NP	a method described earlier -LRB- Takami et al. , 2002b -RRB-	7296
@NP	a method	7296
@NP	earlier -LRB- Takami et al. , 2002b -RRB-	7315
@NP	earlier	7315
@NP	Takami	7324
@NP	et al. , 2002b	7331
@NP	et al.	7331
@NP	2002b	7339
@NP	95-98 %	7363
@NP	Olfactory ensheathing glia	7371
@NP	cultures of OEG	7415
@NP	cultures	7415
@NP	OEG	7427
@NP	the nerve fiber	7450
@NP	layer	7466
@NP	the olfactory bulb	7475
@NP	adult female Fischer rats	7497
@NP	Harlan Co	7524
@NP	a procedure modified from one described previously	7541
@NP	a procedure	7541
@NP	one described previously	7567
@NP	one	7567
@NP	Ram	7593
@NP	n-Cueto et al. , 1998	7597
@NP	n-Cueto	7597
@NP	et al.	7605
@NP	1998	7613
@NP	Care	7620
@NP	the inclusion of non-nerve fiber layer bulb tissue	7647
@NP	the inclusion	7647
@NP	non-nerve fiber layer bulb tissue	7664
@NP	the pia	7703
@NP	OEG	7724
@NP	the Ram -- n-Cueto	7757
@NP	the Ram	7757
@NP	n-Cueto	7765
@NP	et al. -LRB- 1998 -RRB- method ,	7773
@NP	et al.	7773
@NP	1998	7781
@NP	method	7787
@NP	5 days	7812
@NP	forskolin -LRB- 0.8 µg/mL -RRB- and pituitary extract -LRB- 2 µg/mL -RRB-	7822
@NP	forskolin	7822
@NP	0.8 µg/mL	7833
@NP	pituitary extract	7848
@NP	2 µg/mL	7867
@NP	DMEM/F12/10 % FBS before purification	7879
@NP	DMEM/F12/10 % FBS	7879
@NP	purification	7903
@NP	p75 immuno-panning	7919
@NP	Takami	7954
@NP	et al. -LRB- 2002b -RRB-	7961
@NP	et al.	7961
@NP	2002b	7969
@NP	A second period in mitogens	7977
@NP	A second period	7977
@NP	mitogens	7996
@NP	confluency for transplantation	8028
@NP	confluency	8028
@NP	transplantation	8043
@NP	the purity	8069
@NP	SCs except that p75 rather than S100	8095
@NP	SCs	8095
@NP	that p75 rather than S100	8106
@NP	that p75	8106
@NP	S100	8127
@NP	Hoechst nuclear staining	8146
@NP	Purity	8172
@NP	94-98 %	8195
@NP	Animals Adult female Fischer rats -LRB- Harlan Co. , n = 92 ; 160-180 g -RRB-	8203
@NP	Animals Adult female Fischer rats	8203
@NP	Animals	8203
@NP	Adult female Fischer rats	8211
@NP	Harlan Co. , n = 92 ; 160-180 g	8238
@NP	Harlan Co.	8238
@NP	n = 92 ; 160-180 g	8250
@NP	n = 92	8250
@NP	n	8250
@NP	92	8254
@NP	160-180 g	8258
@NP	NIH and USDA guidelines	8294
@NP	The Institutional Animal Care and Use Committee of the University of Miami	8319
@NP	The Institutional Animal Care and Use Committee	8319
@NP	the University of Miami	8370
@NP	the University	8370
@NP	Miami	8388
@NP	all animal procedures	8403
@NP	The rats	8426
@NP	anesthetized with 1Ð2 % halothane	8440
@NP	1Ð2 %	8458
@NP	a mixture of 70 % nitrous oxide and 30 % oxygen	8476
@NP	a mixture	8476
@NP	70 % nitrous oxide and 30 % oxygen	8489
@NP	70 % nitrous oxide	8489
@NP	30 % oxygen	8511
@NP	An adequate level of anesthesia	8523
@NP	An adequate level	8523
@NP	anesthesia	8544
@NP	the corneal reflex and withdrawal	8584
@NP	the corneal reflex	8584
@NP	withdrawal	8607
@NP	painful stimuli for the hindlimbs	8621
@NP	painful stimuli	8621
@NP	the hindlimbs	8641
@NP	The back region	8656
@NP	betadine	8713
@NP	Lacrilube ophthalmic ointment -LRB- Allergan Pharmaceuticals , Irvine , CA -RRB-	8723
@NP	Lacrilube ophthalmic ointment	8723
@NP	Allergan Pharmaceuticals	8754
@NP	Irvine	8780
@NP	CA	8788
@NP	the eyes to prevent drying	8807
@NP	bicillin -LRB- 0.02 mL/100 mg body weight , 300 U/mL , i.m. ; J.	8839
@NP	bicillin -LRB- 0.02 mL/100 mg body weight , 300 U/mL , i.m. ;	8839
@NP	bicillin	8839
@NP	0.02 mL/100 mg body weight , 300 U/mL , i.m.	8849
@NP	0.02 mL/100	8849
@NP	mg body weight , 300 U/mL , i.m.	8861
@NP	mg body weight	8861
@NP	300 U/mL	8877
@NP	i.m.	8887
@NP	J.	8893
@NP	Buck , Inc. , Owings Mills , MO -RRB-	8896
@NP	Buck	8896
@NP	Inc. , Owings Mills , MO -RRB-	8902
@NP	Inc.	8902
@NP	Owings Mills	8908
@NP	MO	8922
@NP	surgery	8963
@NP	the rats	8972
@NP	a heating pad	8994
@NP	the body temperature	9020
@NP	37 ± 0.5 °C	9044
@NP	37 ±	9044
@NP	0.5 °C	9049
@NP	Contusion injury .	9056
@NP	Contusion	9056
@NP	injury	9066
@NP	Contusion injury	9074
@NP	the weight drop device	9106
@NP	New	9142
@NP	York University -LRB- Gruner , 1992 -RRB-	9146
@NP	York University	9146
@NP	Gruner	9163
@NP	1992	9171
@NP	anesthesia	9188
@NP	a vertical incision	9200
@NP	the thoracic vertebra and the superficial muscle	9235
@NP	the thoracic vertebra	9235
@NP	the superficial muscle	9261
@NP	skin	9288
@NP	A laminectomy performed at thoracic vertebra T8	9304
@NP	A laminectomy	9304
@NP	thoracic vertebra T8	9331
@NP	the dorsal surface of the spinal cord	9360
@NP	the dorsal surface	9360
@NP	the spinal cord	9382
@NP	-LRB- T9 -RRB- without disrupting the dura mater	9409
@NP	-LRB- T9 -RRB-	9409
@NP	the dura mater	9433
@NP	Stabilization clamps	9449
@NP	the vertebrae at T6 and T12	9489
@NP	the vertebrae	9489
@NP	T6 and T12	9506
@NP	the column	9528
@NP	impact	9546
@NP	The exposed spinal cord	9554
@NP	a 10.0-g rod	9613
@NP	a height of 12.5 mm	9631
@NP	a height	9631
@NP	12.5 mm	9643
@NP	The contusion impact height , velocity and compression	9652
@NP	The contusion impact height	9652
@NP	velocity	9681
@NP	compression	9694
@NP	Animals -LRB- n = 4 -RRB-	9722
@NP	Animals	9722
@NP	n	9731
@NP	4	9735
@NP	height or velocity errors	9769
@NP	6 %	9804
@NP	the compression distance	9813
@NP	the range of 1.35-1.75 mm	9853
@NP	the range	9853
@NP	1.35-1.75 mm	9866
@NP	injury	9886
@NP	the muscles	9894
@NP	layers	9922
@NP	the skin	9933
@NP	metal wound clips	9954
@NP	The rats	9973
@NP	a warmed cage with water and food easily accessible	10009
@NP	a warmed cage	10009
@NP	water and food	10028
@NP	Bicillin	10062
@NP	2 , 4 , and 6 days	10097
@NP	2	10097
@NP	4	10100
@NP	6 days	10107
@NP	injury	10120
@NP	The rats	10128
@NP	12 weeks	10157
@NP	injury	10172
@NP	Administration of methylprednisolone and interleukin - 10 .	10180
@NP	Administration of methylprednisolone and interleukin	10180
@NP	Administration	10180
@NP	methylprednisolone and interleukin	10198
@NP	10	10234
@NP	MP sodium succinate intravenously -LRB- Upjohn Company , Kalamazoo , MI -RRB-	10261
@NP	MP sodium succinate intravenously	10261
@NP	MP sodium succinate	10261
@NP	Upjohn Company	10296
@NP	Kalamazoo	10312
@NP	MI	10323
@NP	a small incision	10328
@NP	the right ventral neck region before injury	10357
@NP	the right ventral neck region	10357
@NP	injury	10394
@NP	the jugular vein	10411
@NP	A polyethylene tube	10429
@NP	PE-50 , 0.28 mm I.D. ; Clay Adams , Parsippany , NJ	10450
@NP	PE-50	10450
@NP	0.28 mm I.D. ; Clay Adams	10457
@NP	0.28 mm I.D.	10457
@NP	Clay Adams	10471
@NP	Parsippany , NJ	10483
@NP	saline	10511
@NP	3-5 mm	10536
@NP	the vein	10548
@NP	7-0 silk sutures	10577
@NP	The free end of the tube	10595
@NP	The free end	10595
@NP	the tube	10611
@NP	the skin	10637
@NP	the body	10677
@NP	a small opening	10694
@NP	the dorsal neck region -LRB- Chen et al. , 1996 ; Oudega et al. , 1999 -RRB-	10713
@NP	the dorsal neck region	10713
@NP	Chen	10737
@NP	et al. , 1996 ; Oudega et al. , 1999	10742
@NP	et al.	10742
@NP	1996 ; Oudega et al.	10750
@NP	1996	10750
@NP	Oudega et al.	10756
@NP	Oudega	10756
@NP	et al.	10763
@NP	1999	10771
@NP	contusion	10788
@NP	MP	10799
@NP	30 mg/kg body weight	10803
@NP	i.v.	10857
@NP	5 minutes and the animals	10866
@NP	5 minutes	10866
@NP	the animals	10880
@NP	their cages	10909
@NP	MP	10933
@NP	catheter at 2	10963
@NP	catheter	10963
@NP	2	10975
@NP	4 hours	10981
@NP	IL	11002
@NP	10	11006
@NP	30 mg/kg	11010
@NP	recombinant human IL-10	11022
@NP	gift of Shering - Plough Pharmaceuticals , Kenilworth , NJ	11047
@NP	gift of Shering	11047
@NP	gift	11047
@NP	Plough Pharmaceuticals , Kenilworth , NJ	11064
@NP	Plough Pharmaceuticals	11064
@NP	Kenilworth , NJ	11088
@NP	these animals intraperitoneally -LRB- i.p. -RRB-	11129
@NP	these animals intraperitoneally	11129
@NP	these animals	11129
@NP	30 minutes	11168
@NP	injury	11185
@NP	Controls	11193
@NP	lactated RingerÕs solution	11225
@NP	i.v. at 5 minutes	11257
@NP	i.v.	11257
@NP	5 minutes	11265
@NP	2 and 4 hours	11280
@NP	30 minutes after injury	11318
@NP	30 minutes	11318
@NP	injury	11335
@NP	Rats	11343
@NP	six experimental groups	11366
@NP	control -LRB- n = 15 -RRB- ; MP/IL -10 -LRB- n = 13 -RRB-	11404
@NP	control -LRB- n = 15 -RRB-	11404
@NP	control	11404
@NP	n	11413
@NP	15	11417
@NP	MP/IL -10 -LRB- n = 13 -RRB-	11422
@NP	MP/IL -10	11422
@NP	n	11432
@NP	13	11436
@NP	SC grafted -LRB- n = 14 -RRB-	11441
@NP	SC	11441
@NP	n = 14	11453
@NP	n	11453
@NP	= 14	11455
@NP	MP/IL -10 1 SC grafted	11462
@NP	MP/IL -10 1 SC	11462
@NP	MP/IL -10	11462
@NP	1 SC	11471
@NP	n	11485
@NP	13	11489
@NP	SC/OEG grafted -LRB- n = 13 -RRB-	11494
@NP	SC/OEG	11494
@NP	n = 13	11510
@NP	n	11510
@NP	= 13	11512
@NP	MP/IL -10 1 SC/OEG grafted -LRB- n = 14 -RRB-	11519
@NP	MP/IL -10 1 SC/OEG	11519
@NP	MP/IL -10	11519
@NP	1 SC/OEG	11528
@NP	n = 14	11546
@NP	n	11546
@NP	= 14	11548
@NP	these groups	11560
@NP	five rats	11574
@NP	anterograde	11598
@NP	five	11619
@NP	and five for volume analysis and immunochemistry	11647
@NP	and five	11647
@NP	volume analysis and immunochemistry	11660
@NP	some treatment groups , less than five , but at least three	11700
@NP	some treatment groups , less than five	11700
@NP	some treatment groups	11700
@NP	less than five	11723
@NP	at least three	11743
@NP	animals per group	11759
@NP	animals	11759
@NP	group	11771
@NP	analysis	11811
@NP	some	11828
@NP	one or more of the three tracers in the brain -LRB- n = 8 of 30 animals -RRB-	11884
@NP	one or more	11884
@NP	the three tracers in the brain -LRB- n = 8 of 30 animals -RRB-	11899
@NP	the three tracers	11899
@NP	the brain -LRB- n = 8 of 30 animals -RRB-	11920
@NP	the brain	11920
@NP	n = 8 of 30 animals	11931
@NP	n = 8	11931
@NP	n	11931
@NP	8	11935
@NP	30 animals	11940
@NP	All animals	11953
@NP	8 weeks of behavioral testing	11974
@NP	8 weeks	11974
@NP	behavioral testing	11985
@NP	Control rats	12435
@NP	6 µL of DMEM-F12 medium	12467
@NP	6 µL	12467
@NP	DMEM-F12 medium	12475
@NP	All injections	12492
@NP	a 3-minute period	12527
@NP	the injection pipette	12550
@NP	place for an additional 3 minutes	12584
@NP	place	12584
@NP	an additional 3 minutes	12594
@NP	leakage	12630
@NP	withdrawal	12643
@NP	the injections	12661
@NP	the muscle layers and the skin	12677
@NP	the muscle layers	12677
@NP	the skin	12699
@NP	Anterograde axonal and retrograde	12732
@NP	Anterograde	12732
@NP	anterograde tracing	12788
@NP	anterograde	12788
@NP	9 weeks post-injury rats	12809
@NP	9 weeks	12809
@NP	2 % halothane	12859
@NP	10 % biotinylated dextran amine -LRB- BDA ; Molecular Probes , Eugene , OR -RRB-	12877
@NP	10 %	12877
@NP	dextran amine	12894
@NP	BDA ; Molecular Probes	12909
@NP	BDA	12909
@NP	Molecular Probes	12914
@NP	Eugene , OR	12932
@NP	Eugene	12932
@NP	OR	12940
@NP	the hindlimb area of the motor cortex -LRB- 2 x 0.5 µL -RRB-	12994
@NP	the hindlimb area	12994
@NP	the motor cortex -LRB- 2 x 0.5 µL -RRB-	13015
@NP	the motor cortex	13015
@NP	2 x 0.5 µL	13033
@NP	2	13033
@NP	0.5 µL	13037
@NP	10 % dextran-fluorescein -LRB- DFl ; Molecular Probes -RRB-	13046
@NP	10 % dextran-fluorescein	13046
@NP	DFl ; Molecular Probes	13071
@NP	DFl	13071
@NP	Molecular Probes	13076
@NP	the reticular formation -LRB- 2 x 0.3 µL -RRB-	13099
@NP	the reticular formation	13099
@NP	2 x 0.3 µL	13124
@NP	2	13124
@NP	0.3 µL	13128
@NP	10 % dextran-rhodamine -LRB- DRh ; Molecular Probes -RRB-	13140
@NP	10 % dextran-rhodamine	13140
@NP	DRh ; Molecular Probes	13163
@NP	DRh	13163
@NP	Molecular Probes	13168
@NP	the lateral vestibular nuclei -LRB- 2 x 0.2 µL -RRB-	13191
@NP	the lateral vestibular nuclei	13191
@NP	2 x 0.2 µL	13222
@NP	2	13222
@NP	0.2 µL	13226
@NP	Brains from anterogradely-traced animals	13235
@NP	Brains	13235
@NP	anterogradely-traced animals	13247
@NP	accurate tracer injection	13314
@NP	all three areas	13345
@NP	each animal	13364
@NP	retrograde neuronal tracing	13381
@NP	retrograde neuronal	13381
@NP	10 weeks after injury rats	13410
@NP	10 weeks	13410
@NP	injury rats	13425
@NP	2 % halothane	13463
@NP	A total of 0.5 µL of 2 % aqueous fast blue -LRB- FB ; Sigma -RRB-	13477
@NP	A total	13477
@NP	0.5 µL of 2 % aqueous fast blue -LRB- FB ; Sigma -RRB-	13488
@NP	0.5 µL	13488
@NP	2 % aqueous fast blue -LRB- FB ; Sigma -RRB-	13498
@NP	2 % aqueous fast blue	13498
@NP	FB ; Sigma	13520
@NP	FB	13520
@NP	Sigma	13524
@NP	7 mm caudal	13556
@NP	the caudal laminectomy edge	13571
@NP	a small laminectomy between vertebrae T10 and T11	13610
@NP	a small laminectomy	13610
@NP	vertebrae T10 and T11	13638
@NP	vertebrae T10	13638
@NP	T11	13656
@NP	a glass pipette	13667
@NP	diameter , 50 µm	13684
@NP	diameter	13684
@NP	50 µm	13694
@NP	a 1-µL Hamilton syringe	13713
@NP	a micromanipulator -LRB- Takami et al. , 2002b -RRB-	13745
@NP	a micromanipulator	13745
@NP	Takami	13765
@NP	et al. , 2002b	13772
@NP	et al.	13772
@NP	2002b	13780
@NP	All injections	13788
@NP	a 3-minute period	13823
@NP	the injection pipette	13846
@NP	place for an additional 3 minutes	13880
@NP	place	13880
@NP	an additional 3 minutes	13890
@NP	leakage	13926
@NP	withdrawal	13939
@NP	the injection	13957
@NP	the muscles and skin	13972
@NP	the muscles	13972
@NP	skin	13988
@NP	layers	14008
@NP	Histology	14016
@NP	12 weeks after injury	14029
@NP	12 weeks	14029
@NP	injury	14044
@NP	all rats	14052
@NP	2.57 mg ketamine	14080
@NP	0.51 mg xylazine	14098
@NP	0.09 mg acepromazine per 50 g body weight	14120
@NP	0.09 mg acepromazine	14120
@NP	50 g body weight	14145
@NP	phosphate-buffered , 4 % paraformaldehyde -LRB- 0.1 M , pH 7.4 -RRB-	14196
@NP	phosphate-buffered , 4 % paraformaldehyde	14196
@NP	0.1 M	14237
@NP	pH 7.4	14244
@NP	Takami	14253
@NP	et al. , 2002b	14260
@NP	et al.	14260
@NP	2002b	14268
@NP	The T8Ð10 thoracic spinal cord segments	14276
@NP	9 mm	14317
@NP	the complete lesion	14340
@NP	either phosphate-buffered 10 % gelatin solution	14392
@NP	10 %	14418
@NP	Difco Laboratories	14440
@NP	Detroit	14460
@NP	MI	14469
@NP	Oudega	14474
@NP	et al. , 1994	14481
@NP	et al.	14481
@NP	1994	14489
@NP	paraffin to prevent further damage during histological procedures	14501
@NP	further damage	14521
@NP	histological procedures	14543
@NP	Gelatin-embedded cord segments	14568
@NP	30 µm thick sagittal sections	14613
@NP	30 µm	14613
@NP	Sections	14684
@NP	PBS -LRB- 0.1 M , pH 7.4 -RRB-	14711
@NP	PBS	14711
@NP	0.1 M	14716
@NP	pH 7.4	14723
@NP	4 ¡ C	14745
@NP	further processing	14755
@NP	Gelatin embedding	14775
@NP	the tissue	14812
@NP	fluorescent tracers and paraffin embedding	14833
@NP	fluorescent tracers	14833
@NP	paraffin embedding	14857
@NP	the intensity of this fluorescence	14887
@NP	the intensity	14887
@NP	this fluorescence	14904
@NP	The brainstem and cerebral cortex	14923
@NP	The brainstem	14923
@NP	cerebral cortex	14941
@NP	30 µm thick transverse sections	14971
@NP	a freezing microtome	15009
@NP	analysis of retrograde tracing or anterograde tracer injection sites	15034
@NP	analysis	15034
@NP	retrograde tracing or anterograde tracer injection sites	15046
@NP	retrograde tracing	15046
@NP	anterograde tracer injection sites	15068
@NP	Every 10th transverse section	15104
@NP	gelatin-coated slides	15151
@NP	Vectorshield mounting medium -LRB- Vector Laboratories , Burlingame , CA -RRB-	15195
@NP	Vectorshield mounting medium	15195
@NP	Vector Laboratories	15225
@NP	Burlingame	15246
@NP	CA	15258
@NP	Paraffin-embedded cord segments	15263
@NP	10-µm-thick sagittal sections	15309
@NP	histological and immunohistochemical staining	15359
@NP	These thinner sections	15406
@NP	better study of damaged vs normal-appearing tissue after staining	15437
@NP	better study	15437
@NP	vs normal-appearing tissue after staining	15461
@NP	normal-appearing tissue after staining	15464
@NP	normal-appearing tissue	15464
@NP	staining	15494
@NP	Estimation of volumes .	15504
@NP	Estimation	15504
@NP	volumes	15518
@NP	Every 10th sagittal section of the paraffin-embedded T8Ð10 segmentÑthat	15527
@NP	Every 10th sagittal section	15527
@NP	the paraffin-embedded T8Ð10 segmentÑthat	15558
@NP	every 100-µm interval	15603
@NP	the width of the spinal cord -LRB- 14-16 sections per spinal cord -RRB- Ñwas	15634
@NP	the width	15634
@NP	the spinal cord -LRB- 14-16 sections per spinal cord -RRB- Ñwas	15647
@NP	14-16 sections per spinal cord	15664
@NP	14-16 sections	15664
@NP	spinal cord	15683
@NP	slides	15713
@NP	haematoxylin , eosin and luxol	15734
@NP	Pro-Texx	15807
@NP	medium -LRB- Baxter Diagnostics , Deerfield , IL -RRB-	15825
@NP	medium	15825
@NP	Baxter Diagnostics	15833
@NP	Deerfield	15853
@NP	IL	15864
@NP	volume -LRB- area 3 section thickness -RRB-	15881
@NP	volume	15881
@NP	area 3 section thickness	15889
@NP	an image analysis computer system	15921
@NP	Universal	15956
@NP	West Chester	15967
@NP	PA	15981
@NP	each section	15989
@NP	the total volume	16003
@NP	the 9-mm-long cord segment with the lesion epicenter in the middle	16023
@NP	the 9-mm-long cord segment	16023
@NP	the lesion epicenter in the middle	16055
@NP	the lesion epicenter	16055
@NP	the middle	16079
@NP	the cavity and damaged tissue volumes	16118
@NP	the cavity	16118
@NP	damaged tissue volumes	16133
@NP	tissue	16181
@NP	normal-appearing tissue	16216
@NP	an increased density of small -LRB- immune -RRB- cells , fragmented myelin	16243
@NP	an increased density	16243
@NP	small -LRB- immune -RRB- cells , fragmented myelin	16267
@NP	small -LRB- immune -RRB- cells	16267
@NP	the absence of healthy appearing neurons	16311
@NP	the absence	16311
@NP	healthy appearing neurons	16326
@NP	The volumes of each section	16353
@NP	The volumes	16353
@NP	each section	16368
@NP	rat	16397
@NP	10	16424
@NP	every 10th section	16428
@NP	the total volume of the 9-mm-long cord segment	16469
@NP	the total volume	16469
@NP	the 9-mm-long cord segment	16489
@NP	the volumes of cavitated and damaged spinal tissue	16520
@NP	the volumes	16520
@NP	spinal tissue	16557
@NP	The volume of normal - appearing spinal tissue within the 9-mm-long cord segment	16572
@NP	The volume	16572
@NP	normal - appearing spinal tissue within the 9-mm-long cord segment	16586
@NP	normal	16586
@NP	appearing spinal tissue within the 9-mm-long cord segment	16594
@NP	appearing spinal tissue	16594
@NP	the 9-mm-long cord segment	16625
@NP	the added volumes	16682
@NP	cavitated and damaged tissue from the volume of the whole cord segment	16703
@NP	cavitated and damaged tissue	16703
@NP	the volume of the whole cord segment	16737
@NP	the volume	16737
@NP	the whole cord segment	16751
@NP	the total cord volume	16778
@NP	cavity , damaged and normal-appearing tissue volumes	16809
@NP	cavity	16809
@NP	damaged	16817
@NP	normal-appearing tissue volumes	16829
@NP	this value for normal-appearing tissue	16871
@NP	this value	16871
@NP	normal-appearing tissue	16886
@NP	the percentage	16927
@NP	the total volume of the 9	16945
@NP	the total volume	16945
@NP	the 9	16965
@NP	mm-long cord segment from the same cord level in uninjured rats	16972
@NP	mm-long cord segment	16972
@NP	the same cord level in uninjured rats	16998
@NP	the same cord level	16998
@NP	uninjured rats	17021
@NP	Six uninjured and untreated rats	17037
@NP	uninjured	17041
@NP	the mean volume of the normal T8Ð10 spinal cord	17108
@NP	the mean volume	17108
@NP	the normal T8Ð10 spinal cord	17127
@NP	Quantitative assessment of traced fibers .	17157
@NP	Quantitative assessment	17157
@NP	traced fibers	17184
@NP	, or DRh-labeled axons	17209
@NP	DRh-labeled	17214
@NP	every fourth section	17249
@NP	the T8Ð10 cord segments	17273
@NP	i.e. , every 120-µm interval spanning the width of the spinal cord	17298
@NP	i.e.	17298
@NP	every 120-µm interval spanning the width of the spinal cord	17304
@NP	every 120-µm interval	17304
@NP	the width of the spinal cord	17335
@NP	the width	17335
@NP	the spinal cord	17348
@NP	axons	17377
@NP	Nickel-enhanced avidinÐbiotinÐperoxidase staining	17405
@NP	Oudega and Hagg , 1999	17456
@NP	Oudega	17456
@NP	Hagg , 1999	17467
@NP	Hagg	17467
@NP	1999	17473
@NP	DFl	17487
@NP	DRh-labeled fibers	17496
@NP	fluorescence microscopy	17535
@NP	The number of labeled axons	17560
@NP	The number	17560
@NP	labeled axons	17574
@NP	all	17615
@NP	axons	17627
@NP	imaginary lines	17642
@NP	perpendicular to the rostralÐcaudal cord axis at 2,500 µm rostral and caudal	17665
@NP	the rostralÐcaudal cord axis at 2,500 µm	17682
@NP	the rostralÐcaudal cord axis	17682
@NP	2,500 µm	17714
@NP	the epicenter	17745
@NP	the lesion epicenter	17766
@NP	The numbers in each section -LRB- 10Ð12 complete sections per spinal cord -RRB-	17788
@NP	The numbers	17788
@NP	each section -LRB- 10Ð12 complete sections per spinal cord -RRB-	17803
@NP	each section	17803
@NP	10Ð12 complete sections per spinal cord	17817
@NP	10Ð12 complete sections	17817
@NP	spinal cord	17845
@NP	rat	17874
@NP	4	17896
@NP	the final number of labeled axons	17908
@NP	the final number	17908
@NP	labeled axons	17928
@NP	numbers of neurons labeled by retrograde tracing	17953
@NP	numbers	17953
@NP	neurons labeled by retrograde tracing	17964
@NP	neurons	17964
@NP	retrograde tracing	17983
@NP	retrograde	17983
@NP	every tenth section	18003
@NP	the rat brain atlas -LRB- Paxinos , 1998 -RRB-	18057
@NP	the rat brain atlas	18057
@NP	Paxinos	18078
@NP	1998	18087
@NP	The number of FBlabeled neurons	18094
@NP	The number	18094
@NP	FBlabeled neurons	18108
@NP	the sensorimotor cortex , reticular formation and vestibular nuclei	18141
@NP	the sensorimotor cortex	18141
@NP	reticular formation	18166
@NP	vestibular nuclei	18190
@NP	These numbers	18209
@NP	the total number	18239
@NP	retrogradely-traced neurons	18259
@NP	each region	18302
@NP	the following formula	18327
@NP	-LSB- -LRB- rostral to caudal length of region -LRB- µm -RRB- / 30 µm -RRB- 3	18350
@NP	-LSB-	18350
@NP	rostral to caudal length of region -LRB- µm -RRB- / 30 µm	18352
@NP	rostral	18352
@NP	caudal length	18363
@NP	region -LRB- µm -RRB- / 30 µm	18380
@NP	region -LRB- µm -RRB-	18380
@NP	region	18380
@NP	µm	18388
@NP	30 µm	18392
@NP	3	18399
@NP	neuron sum/number of sections analyzed for the region	18410
@NP	neuron sum/number	18410
@NP	sections analyzed for the region	18431
@NP	sections	18431
@NP	the region	18453
@NP	the final summed number of labeled neurons for each region in each animal	18477
@NP	the final summed number	18477
@NP	labeled neurons for each region in each animal	18504
@NP	labeled neurons	18504
@NP	each region in each animal	18524
@NP	each region	18524
@NP	each animal	18539
@NP	Immunohistochemistry .	18552
@NP	Every tenth sagittal section	18574
@NP	rabbit polyclonal antibodies , or both , following an earlier described	18662
@NP	rabbit polyclonal antibodies , or both ,	18662
@NP	rabbit polyclonal antibodies	18662
@NP	both	18695
@NP	an earlier described	18711
@NP	an earlier	18711
@NP	Takami	18742
@NP	et al. , 2002b	18749
@NP	et al.	18749
@NP	2002b	18757
@NP	The polyclonal antibodies used	18765
@NP	The polyclonal antibodies	18765
@NP	anti-serotonin -LRB- 5-HT , 1:500 ; Incstar Corp. , Stillwater , MN -RRB-	18801
@NP	anti-serotonin	18801
@NP	5-HT , 1:500 ; Incstar Corp. , Stillwater , MN	18817
@NP	5-HT	18817
@NP	1:500 ; Incstar Corp. , Stillwater	18823
@NP	1:500	18823
@NP	Incstar Corp. , Stillwater	18830
@NP	Incstar Corp.	18830
@NP	Stillwater	18845
@NP	MN	18857
@NP	anti-glial fibrillary acidic protein	18865
@NP	GFAP , 1:400 ; Dako , Carpinteria , CA	18903
@NP	GFAP	18903
@NP	1:400 ; Dako	18909
@NP	1:400	18909
@NP	Dako	18916
@NP	Carpinteria , CA	18922
@NP	The monoclonal antibody used	18940
@NP	The monoclonal antibody	18940
@NP	anti-low-affinity nerve growth factor receptor -LSB- p75 -LRB- 192 IgG -RRB-	18973
@NP	anti-low-affinity nerve growth factor receptor	18973
@NP	p75 -LRB- 192 IgG -RRB-	19021
@NP	p75	19021
@NP	192 IgG	19026
@NP	1:2	19036
@NP	gift from Dr.	19041
@NP	gift	19041
@NP	Dr.	19051
@NP	E.	19055
@NP	Shooter , Stanford University -RSB- .	19058
@NP	Shooter	19058
@NP	Stanford University -RSB-	19067
@NP	The secondary antibodies used	19089
@NP	The secondary antibodies	19089
@NP	Alexa 488-conjugated goat anti-rabbit	19124
@NP	1:200 ; Molecular Probes	19163
@NP	1:200	19163
@NP	Molecular Probes	19170
@NP	Alexa 594-conjugated rabbit anti-mouse -LRB- 1:200 ; Molecular Probes -RRB-	19192
@NP	Alexa 594-conjugated rabbit	19192
@NP	1:200 ; Molecular Probes	19232
@NP	1:200	19232
@NP	Molecular Probes	19239
@NP	The sections	19258
@NP	gelatin-coated glass slides	19289
@NP	Vectorshield	19337
@NP	medium	19359
@NP	Determination of 5HT fiber growth .	19367
@NP	Determination	19367
@NP	5HT fiber growth	19384
@NP	The numbers of 5HT-labeled axons	19402
@NP	The numbers	19402
@NP	5HT-labeled axons	19417
@NP	all	19463
@NP	axons	19475
@NP	imaginary lines	19490
@NP	the rostralÐcaudal axis of the spinal cord at 500 µm rostral and 500 µm caudal	19530
@NP	the rostralÐcaudal axis	19530
@NP	the spinal cord at 500 µm rostral and 500 µm caudal	19557
@NP	the spinal cord	19557
@NP	500 µm rostral and 500 µm caudal	19576
@NP	500 µm rostral	19576
@NP	500 µm caudal	19595
@NP	the edge of the graft	19612
@NP	the edge	19612
@NP	the graft	19624
@NP	the center of the graft	19653
@NP	the center	19653
@NP	the graft	19667
@NP	The graft	19678
@NP	double-labeling the sections with p75	19725
@NP	double-labeling the sections	19725
@NP	p75	19759
@NP	the transplant	19775
@NP	The number	19791
@NP	fibers from the sections -LRB- 14-16 complete sections per spinal cord -RRB-	19805
@NP	fibers	19805
@NP	the sections -LRB- 14-16 complete sections per spinal cord -RRB-	19817
@NP	the sections	19817
@NP	14-16 complete sections per spinal cord	19831
@NP	14-16 complete sections	19831
@NP	spinal cord	19859
@NP	rat	19905
@NP	the number of fibers per section	19922
@NP	the number	19922
@NP	fibers per section	19936
@NP	fibers	19936
@NP	section	19947
@NP	the totals	19956
@NP	the number of sections examined	19988
@NP	the number	19988
@NP	sections examined	20002
@NP	sections	20002
@NP	Quantification of the intensity of GFAP immunoreactivity .	20021
@NP	Quantification	20021
@NP	the intensity	20039
@NP	GFAP immunoreactivity	20056
@NP	Digital images of GFAP immunoreactivity	20079
@NP	Digital images	20079
@NP	GFAP immunoreactivity	20097
@NP	2-mm-wide areas of the spinal cord rostral	20133
@NP	2-mm-wide areas	20133
@NP	the spinal cord rostral	20152
@NP	a perpendicular line	20193
@NP	the center	20217
@NP	the injury	20231
@NP	graft	20243
@NP	four sections -LRB- two sections on either side of the central canal -RRB-	20252
@NP	four sections	20252
@NP	two sections on either side of the central canal	20267
@NP	two sections	20267
@NP	either side of the central canal	20283
@NP	either side	20283
@NP	the central canal	20298
@NP	each animal -LRB- 5/group -RRB- at 12 weeks	20322
@NP	each animal -LRB- 5/group -RRB-	20322
@NP	each animal	20322
@NP	5/group	20335
@NP	12 weeks	20347
@NP	GFAP	20369
@NP	a marker for astrogliosis	20386
@NP	a marker	20386
@NP	astrogliosis	20399
@NP	These images	20413
@NP	intensity-measuring software	20451
@NP	van der Lest et al. , University of Nijmegen ,	20481
@NP	van der	20481
@NP	et al. , University of Nijmegen ,	20494
@NP	et al.	20494
@NP	University of Nijmegen	20502
@NP	University	20502
@NP	Nijmegen	20516
@NP	The Netherlands	20526
@NP	The software	20544
@NP	units , the total pixel intensity of the GFAP staining in each image	20603
@NP	units	20603
@NP	the total pixel intensity of the GFAP staining in each image	20610
@NP	the total pixel intensity	20610
@NP	the GFAP staining in each image	20639
@NP	the GFAP staining	20639
@NP	each image	20660
@NP	These values	20672
@NP	the four sections	20709
@NP	a mean	20735
@NP	GFAP intensity both rostral and caudal per animal	20742
@NP	GFAP intensity both rostral	20742
@NP	GFAP intensity	20742
@NP	rostral	20762
@NP	caudal per animal	20774
@NP	caudal	20774
@NP	animal	20785
@NP	Behavioral Testing BBB Open Field Locomotor Score .	20793
@NP	Behavioral Testing	20793
@NP	BBB Open Field Locomotor Score	20812
@NP	Hindlimb performance	20844
@NP	the open field locomotor test	20885
@NP	Basso	20928
@NP	et al. -LRB- 1995 , 1996 -RRB-	20934
@NP	et al.	20934
@NP	1995	20942
@NP	1996	20948
@NP	Two observers , unaware of the experimental procedures ,	20955
@NP	Two observers	20955
@NP	the experimental procedures	20981
@NP	the test	21020
@NP	a week	21034
@NP	8 weeks	21045
@NP	A BBB sub-score	21054
@NP	some animals	21096
@NP	a recovery pattern	21119
@NP	the progression of the BBB score -LRB- Popovich et al. , 1999 -RRB-	21158
@NP	the progression	21158
@NP	the BBB score -LRB- Popovich et al. , 1999 -RRB-	21177
@NP	the BBB score	21177
@NP	Popovich	21192
@NP	et al. , 1999	21201
@NP	et al.	21201
@NP	1999	21209
@NP	Grid	21216
@NP	Test	21226
@NP	Deficits in descending motor control	21232
@NP	Deficits	21232
@NP	descending motor control	21244
@NP	8 weeks	21286
@NP	navigation	21307
@NP	a 1-m-long runway	21325
@NP	irregularly assigned gaps -LRB- 0.5 Ð5 cm -RRB- between round metal bars	21348
@NP	irregularly assigned gaps -LRB- 0.5 Ð5 cm -RRB-	21348
@NP	irregularly assigned gaps	21348
@NP	0.5 Ð5 cm	21375
@NP	round metal bars	21393
@NP	Metz	21438
@NP	et al. -LRB- 2000 -RRB-	21443
@NP	et al.	21443
@NP	2000	21451
@NP	this runway	21467
@NP	animals	21493
@NP	their limbs	21518
@NP	the bars	21533
@NP	baseline training and postoperative testing	21546
@NP	baseline training	21546
@NP	postoperative testing	21568
@NP	every animal	21591
@NP	the grid	21617
@NP	at least three times	21626
@NP	The number of footfalls -LRB- errors -RRB-	21648
@NP	The number	21648
@NP	footfalls -LRB- errors -RRB-	21662
@NP	footfalls	21662
@NP	errors	21673
@NP	each crossing	21696
@NP	each	21696
@NP	a mean error rate	21714
@NP	Footprint analysis .	21748
@NP	Footprint	21748
@NP	analysis	21758
@NP	Footprint analysis	21768
@NP	8 weeks using a protocol modified from de Medinaceli et al. -LRB- 1982 -RRB-	21804
@NP	8 weeks	21804
@NP	a protocol modified from de Medinaceli et al. -LRB- 1982 -RRB-	21818
@NP	a protocol	21818
@NP	de Medinaceli et al. -LRB- 1982 -RRB-	21843
@NP	de Medinaceli et al.	21843
@NP	The animalÕs hind paws	21872
@NP	footprints	21910
@NP	paper covering a narrow runway of 1 m in length and 7 cm in width	21934
@NP	paper	21934
@NP	a narrow runway of 1 m in length and 7 cm in width	21949
@NP	a narrow runway	21949
@NP	1 m in length and 7 cm in width	21968
@NP	1 m in length	21968
@NP	1 m	21968
@NP	length	21975
@NP	7 cm in width	21986
@NP	7 cm	21986
@NP	width	21994
@NP	This	22001
@NP	the direction of each step	22019
@NP	the direction	22019
@NP	each step	22036
@NP	standardized in line	22050
@NP	standardized	22050
@NP	line	22066
@NP	A series of at least eight sequential steps	22072
@NP	A series	22072
@NP	at least eight sequential steps	22084
@NP	the mean values	22138
@NP	each measurement of limb rotation , stride length and base of support	22158
@NP	each measurement	22158
@NP	limb rotation , stride length and base of support	22178
@NP	limb rotation	22178
@NP	stride length and base of support	22193
@NP	stride length and base	22193
@NP	support	22219
@NP	The base of support	22228
@NP	The base	22228
@NP	support	22240
@NP	the core-to-core distance of the central pads of the hind paws	22276
@NP	the core-to-core distance	22276
@NP	the central pads of the hind paws	22305
@NP	the central pads	22305
@NP	the hind paws	22325
@NP	The limb rotation	22340
@NP	the angle	22373
@NP	the intersection of the line	22393
@NP	the intersection	22393
@NP	the line	22413
@NP	the print of the third digit and the line	22430
@NP	the print	22430
@NP	the third digit and the line	22443
@NP	the third digit	22443
@NP	the line	22463
@NP	the central pad parallel	22480
@NP	the walking direction	22508
@NP	Stride length	22531
@NP	the central pads of two consecutive prints on each side	22566
@NP	the central pads	22566
@NP	two consecutive prints on each side	22586
@NP	two consecutive prints	22586
@NP	each side	22612
@NP	Statistical Analysis One-way ANOVA followed by FisherÕs	22623
@NP	Statistical Analysis One-way ANOVA	22623
@NP	FisherÕs	22670
@NP	least-significant difference	22689
@NP	PLSD	22719
@NP	test	22725
@NP	results of the tissue volume analysis , retrograde neuronal tracing	22753
@NP	results of the tissue volume analysis	22753
@NP	results	22753
@NP	the tissue volume analysis	22764
@NP	immunohistochemical detection of specific fiber types	22824
@NP	immunohistochemical detection	22824
@NP	specific fiber types	22857
@NP	staining intensities of GFAP	22882
@NP	staining intensities	22882
@NP	GFAP	22906
@NP	Multiple factor repeated ANOVA followed by the Tukey-Kramer test	22912
@NP	Multiple factor	22912
@NP	ANOVA followed by the Tukey-Kramer test	22937
@NP	ANOVA	22937
@NP	the Tukey-Kramer test	22955
@NP	comparison of weekly functional recovery patterns	22990
@NP	comparison	22990
@NP	weekly functional recovery patterns	23004
@NP	injury	23046
@NP	Differences	23054
@NP	p < 0.05 * , ,0.01 ** , and ,0.001 ***	23115
@NP	p < 0.05 * , ,0.01 **	23115
@NP	p	23115
@NP	< 0.05 * , ,0.01 **	23117
@NP	<	23117
@NP	0.05 * , ,0.01 **	23119
@NP	0.05 * , ,0.01	23119
@NP	0.05 *	23119
@NP	,0.01	23126
@NP	,0.001 ***	23139
@NP	All errors	23150
@NP	standard deviations	23174
@NP	RESULTS	23196
@NP	1	23210
@NP	SUMMARY OF TISSUE VOLUME ANALYSIS OF A 9-MM CORD SEGMENT	23213
@NP	SUMMARY	23213
@NP	TISSUE VOLUME ANALYSIS OF A 9-MM CORD SEGMENT	23224
@NP	TISSUE VOLUME ANALYSIS	23224
@NP	A 9-MM CORD SEGMENT	23250
@NP	THE INJURY TABLE 2	23283
@NP	SUMMARY OF THE BENEFICIAL AND ADVERSE EFFECTS OF EACH TREATMENT FIG. 1 .	23304
@NP	SUMMARY	23304
@NP	THE BENEFICIAL AND ADVERSE EFFECTS	23315
@NP	THE BENEFICIAL	23315
@NP	ADVERSE EFFECTS	23334
@NP	EACH TREATMENT FIG. 1	23353
@NP	MP/IL -10 , cell grafting or the combination	23377
@NP	MP/IL -10	23377
@NP	cell grafting	23387
@NP	the combination	23404
@NP	cavitation	23428
@NP	-LRB- A -RRB- Injured-only control .	23440
@NP	-LRB- A -RRB-	23440
@NP	Injured-only control	23444
@NP	-LRB- B -RRB- MP/IL -10 .	23466
@NP	-LRB- B -RRB-	23466
@NP	MP/IL -10	23470
@NP	-LRB- C -RRB- SC transplant .	23480
@NP	-LRB- C -RRB-	23480
@NP	SC transplant	23484
@NP	-LRB- D -RRB- MP/IL -10 and SC transplant .	23499
@NP	-LRB- D -RRB-	23499
@NP	MP/IL -10 and SC transplant	23503
@NP	MP/IL -10	23503
@NP	SC transplant	23516
@NP	-LRB- E -RRB- SC/OEG transplant .	23531
@NP	-LRB- E -RRB-	23531
@NP	SC/OEG transplant	23535
@NP	-LRB- F -RRB- MP/IL -10 and SC/OEG transplant .	23554
@NP	-LRB- F -RRB-	23554
@NP	MP/IL -10 and SC/OEG transplant	23558
@NP	MP/IL -10	23558
@NP	SC/OEG transplant	23571
@NP	The injury/transplant site	23590
@NP	the middle of the 9-mm-long segment of spinal cord	23623
@NP	the middle	23623
@NP	the 9-mm-long segment of spinal cord	23637
@NP	the 9-mm-long segment	23637
@NP	spinal cord	23662
@NP	Hematoxylin	23675
@NP	eosin	23688
@NP	luxol	23699
@NP	blue-stained sagittal sections from within 200 µm lateral of the central canal	23710
@NP	blue-stained sagittal sections	23710
@NP	200 µm lateral of the central canal	23753
@NP	200 µm lateral	23753
@NP	the central canal	23771
@NP	Bar	23790
@NP	1 mm	23796
@NP	FIG. 2 .	23803
@NP	FIG.	23803
@NP	2	23808
@NP	MP/IL -10 or cell transplantation	23811
@NP	MP/IL -10	23811
@NP	cell transplantation	23823
@NP	total cord volume and normal-appearing tissue volume	23854
@NP	cavitation	23921
@NP	-LRB- A -RRB- High magnification	23933
@NP	A	23934
@NP	image	23956
@NP	an SC-grafted spinal cord	23965
@NP	the border between normal-appearing tissue	23999
@NP	the border	23999
@NP	normal-appearing tissue	24018
@NP	tissue	24063
@NP	white arrows	24085
@NP	The normal-appearing tissue	24100
@NP	viable neurons -LRB- yellow asterisks -RRB-	24137
@NP	viable neurons	24137
@NP	yellow asterisks	24153
@NP	intact myelin and normal cellular density	24172
@NP	Bar	24215
@NP	50 µm	24221
@NP	-LRB- B -RRB- The total cord volume of a 9-mm region of the spinal cord	24228
@NP	-LRB- B -RRB-	24228
@NP	The total cord volume of a 9-mm region of the spinal cord	24232
@NP	The total cord volume	24232
@NP	a 9-mm region of the spinal cord	24257
@NP	a 9-mm region	24257
@NP	the spinal cord	24274
@NP	the injury site	24303
@NP	its center	24322
@NP	-LRB- C -RRB- The volume of cavitation within this 9-mm region	24334
@NP	The volume	24338
@NP	cavitation within this 9-mm region	24352
@NP	cavitation	24352
@NP	this 9-mm region	24370
@NP	a percentage of total cord volume	24400
@NP	a percentage	24400
@NP	total cord volume	24416
@NP	FIG. 3 .	24918
@NP	FIG.	24918
@NP	3	24923
@NP	Anterogradely-traced supraspinal fibers	24926
@NP	SC/OEG grafts	24984
@NP	their numbers	25002
@NP	MP/IL -10	25037
@NP	The number of anterogradely	25047
@NP	The number	25047
@NP	anterogradely	25061
@NP	fibers/section 2500 µm rostral to	25082
@NP	fibers/section 2500 µm rostral	25082
@NP	2500 µm caudal	25129
@NP	the injury epicenter	25147
@NP	the sensorimotor cortex -LRB- BDA -RRB- -LRB- A -RRB-	25171
@NP	the sensorimotor cortex -LRB- BDA -RRB-	25171
@NP	the sensorimotor cortex	25171
@NP	BDA	25196
@NP	A	25202
@NP	the reticular formation -LRB- DRh -RRB- -LRB- B -RRB-	25206
@NP	the reticular formation -LRB- DRh -RRB-	25206
@NP	the reticular formation	25206
@NP	DRh	25231
@NP	B	25237
@NP	the vestibular nuclei -LRB- DFl -RRB- -LRB- C -RRB-	25245
@NP	the vestibular nuclei -LRB- DFl -RRB-	25245
@NP	the vestibular nuclei	25245
@NP	DFl	25268
@NP	C	25274
@NP	The graft	25278
@NP	p75 immunoreactivity	25306
@NP	SC transplant	25330
@NP	, SC transplant with MP/IL -10 ; , SC/OEG transplant ; j , SC/OEG transplant	25345
@NP	SC transplant	25347
@NP	MP/IL -10 ; , SC/OEG transplant ; j , SC/OEG	25366
@NP	MP/IL -10 ; , SC/OEG transplant	25366
@NP	MP/IL -10	25366
@NP	SC/OEG transplant	25378
@NP	j , SC/OEG	25397
@NP	j	25397
@NP	SC/OEG	25400
@NP	MP/IL -10	25423
@NP	FIG. 4 .	25434
@NP	FIG.	25434
@NP	4	25439
@NP	Serotonergic fibers	25442
@NP	SC/OEG grafts	25486
@NP	-LRB- A -RRB- Diagram	25501
@NP	-LRB- A -RRB-	25501
@NP	Diagram	25505
@NP	the three perpendicular lines	25521
@NP	rostral	25551
@NP	the center	25566
@NP	caudal to the graft at which crossing 5HT1 fibers	25585
@NP	caudal	25585
@NP	the graft at which crossing 5HT1 fibers	25595
@NP	the graft	25595
@NP	5HT1 fibers	25623
@NP	-LRB- B -RRB-	25650
@NP	The mean numbers of serotonergic fibers	25654
@NP	The mean numbers	25654
@NP	serotonergic fibers	25674
@NP	present per section 500 µm rostral to and within the transplant site	25694
@NP	present	25694
@NP	section 500 µm rostral	25706
@NP	the transplant site	25743
@NP	11 weeks after transplantation	25763
@NP	11 weeks	25763
@NP	transplantation	25778
@NP	The graft	25795
@NP	p75 immunoreactivity	25823
@NP	SC transplant	25847
@NP	, SC transplant with MP/IL -10 ; , SC/OEG transplant ; j , SC/OEG transplant	25862
@NP	SC transplant	25864
@NP	MP/IL -10 ; , SC/OEG transplant ; j , SC/OEG	25883
@NP	MP/IL -10 ; , SC/OEG transplant	25883
@NP	MP/IL -10	25883
@NP	SC/OEG transplant	25895
@NP	j , SC/OEG	25914
@NP	j	25914
@NP	SC/OEG	25917
@NP	MP/IL -10	25940
@NP	FIG. 5 .	25951
@NP	FIG.	25951
@NP	5	25956
@NP	MP/IL -10 or SC/OEG grafting	25959
@NP	MP/IL -10	25959
@NP	SC/OEG grafting	25971
@NP	the number of reticulospinal , but not corticospinal or vestibulospinal , fibers	25997
@NP	the number	25997
@NP	reticulospinal , but not corticospinal or vestibulospinal , fibers	26011
@NP	the injury/transplant site	26086
@NP	The photographs	26114
@NP	Fast Blue-labeled neurons	26137
@NP	the reticular formation	26166
@NP	labeling below the injury/transplant site after : -LRB- A -RRB- Injury only	26200
@NP	labeling	26200
@NP	the injury/transplant site after : -LRB- A -RRB- Injury only	26215
@NP	the injury/transplant site	26215
@NP	-LRB- A -RRB- Injury only	26249
@NP	-LRB- A -RRB-	26249
@NP	Injury only	26253
@NP	-LRB- B -RRB- MP/IL -10 .	26266
@NP	-LRB- B -RRB-	26266
@NP	MP/IL -10	26270
@NP	-LRB- C -RRB- SC/OEG transplantation .	26280
@NP	-LRB- C -RRB-	26280
@NP	SC/OEG transplantation	26284
@NP	Bar 0 150 µm .	26308
@NP	Bar 0	26308
@NP	150 µm	26314
@NP	FIG. 6 .	26738
@NP	FIG.	26738
@NP	6	26743
@NP	MP/IL -10	26746
@NP	gliosis	26763
@NP	injury	26777
@NP	SC/OEG grafts	26785
@NP	host cord gliosis than SC grafts	26826
@NP	host cord gliosis	26826
@NP	SC grafts	26849
@NP	-LRB- A -RRB- Diagram	26860
@NP	-LRB- A -RRB-	26860
@NP	Diagram	26864
@NP	the rostral and caudal 2 mm	26880
@NP	regions	26913
@NP	either side of a perpendicular line	26924
@NP	either side	26924
@NP	a perpendicular line	26939
@NP	the center of the injury/graft that were photographed to measure GFAP intensity	26963
@NP	the center	26963
@NP	the injury/graft that were photographed to measure GFAP intensity	26977
@NP	the injury/graft	26977
@NP	GFAP intensity	27028
@NP	-LRB- B -RRB-	27044
@NP	The intensity	27048
@NP	GFAP immunoreactivity -LRB- arbitrary units -RRB-	27065
@NP	GFAP immunoreactivity	27065
@NP	arbitrary units	27088
@NP	11 weeks	27108
@NP	, injured-only control ; , MP/IL -10 ; , SC transplant ; , SC transplant	27139
@NP	, injured-only control ; , MP/IL -10	27139
@NP	, injured-only control	27139
@NP	MP/IL	27165
@NP	-10	27170
@NP	SC transplant	27177
@NP	SC transplant	27194
@NP	MP/IL -10	27213
@NP	SC/OEG transplant ; j , SC/OEG transplant	27225
@NP	SC/OEG transplant	27225
@NP	j	27244
@NP	SC/OEG transplant	27247
@NP	SC/OEG	27247
@NP	transplant	27254
@NP	MP/IL -10	27270
@NP	p <	27281
@NP	p	27281
@NP	<	27283
@NP	0.05	27285
@NP	p <	27293
@NP	p	27293
@NP	0.01	27297
@NP	injury-only controls , # p <	27317
@NP	injury-only controls	27317
@NP	# p <	27339
@NP	0.05 as compared to cell only transplants	27344
@NP	cell only	27364
@NP	FIG. 7 .	27388
@NP	FIG.	27388
@NP	7	27393
@NP	Combination of MP/IL -10 and SC/OEG transplantation	27396
@NP	Combination	27396
@NP	MP/IL -10 and SC/OEG transplantation	27411
@NP	MP/IL -10	27411
@NP	SC/OEG transplantation	27424
@NP	early and persistent gross behavioral improvement	27456
@NP	-LRB- A -RRB- Open-field locomotor ability	27507
@NP	-LRB- A -RRB-	27507
@NP	Open-field locomotor ability	27511
@NP	weekly using the BBB score at 1Ð8 weeks post-transplantation	27553
@NP	weekly	27553
@NP	the BBB score	27566
@NP	1Ð8 weeks	27583
@NP	-LRB- B -RRB- Weekly subscore analysis of the BBB score	27615
@NP	-LRB- B -RRB-	27615
@NP	Weekly subscore analysis of the BBB score	27619
@NP	Weekly subscore analysis	27619
@NP	the BBB score	27647
@NP	the number of features above 14	27671
@NP	the number	27671
@NP	features above 14	27685
@NP	features	27685
@NP	14	27700
@NP	the BBB scale	27706
@NP	1Ð8 weeks	27723
@NP	transplantation	27739
@NP	ÐsÐ , injured-only control	27756
@NP	ÐsÐ	27756
@NP	injured-only control	27761
@NP	ÐdÐ MP/IL -10	27783
@NP	ÐdÐ MP/IL	27783
@NP	-10	27792
@NP	ÐuÐ , SC transplant	27797
@NP	ÐuÐ	27797
@NP	SC transplant	27802
@NP	ÐjÐ , SC transplant with MP/IL -10	27817
@NP	ÐjÐ	27817
@NP	SC transplant with MP/IL -10	27822
@NP	SC transplant	27822
@NP	MP/IL -10	27841
@NP	ÐeÐ , SC/OEG transplant	27851
@NP	ÐeÐ	27851
@NP	SC/OEG transplant	27856
@NP	ÐrÐ , SC/OEG transplant with MP/IL -10	27875
@NP	ÐrÐ	27875
@NP	SC/OEG transplant with MP/IL -10	27880
@NP	SC/OEG transplant	27880
@NP	MP/IL -10	27903
@NP	p values : * p <	27913
@NP	p values	27913
@NP	p	27924
@NP	<	27926
@NP	0.05 , ** p <	27928
@NP	0.05	27928
@NP	p <	27936
@NP	p	27936
@NP	<	27938
@NP	0.01	27940
@NP	injury-only controls	27960
@NP	FIG. 8 .	27983
@NP	FIG.	27983
@NP	8	27988
@NP	MP/IL -10 administration or SC transplantation	27991
@NP	MP/IL -10 administration	27991
@NP	SC transplantation	28018
@NP	fine locomotor performance	28046
@NP	8 weeks	28076
@NP	their combination	28089
@NP	outcome	28129
@NP	-LRB- A -RRB- The angle of foot exo-rotation of the hind paws .	28138
@NP	-LRB- A -RRB-	28138
@NP	The angle of foot exo-rotation of the hind paws	28142
@NP	The angle	28142
@NP	foot exo-rotation of the hind paws	28155
@NP	foot exo-rotation	28155
@NP	the hind paws	28176
@NP	-LRB- B -RRB- The distance of the base of support between the hind paws .	28191
@NP	-LRB- B -RRB-	28191
@NP	The distance of the base of support between the hind paws	28195
@NP	The distance	28195
@NP	the base of support between the hind paws	28211
@NP	the base	28211
@NP	support between the hind paws	28223
@NP	support	28223
@NP	the hind paws	28239
@NP	-LRB- C -RRB- The stride length .	28254
@NP	-LRB- C -RRB-	28254
@NP	The stride length	28258
@NP	Tissue Preservation Twelve weeks	28703
@NP	Tissue Preservation	28703
@NP	Twelve weeks	28723
@NP	SCI control spinal cords	28751
@NP	the injury epicenter	28777
@NP	one or more central cavities -LRB- Fig. 1A -RRB-	28815
@NP	one or more central cavities	28815
@NP	Fig. 1A	28845
@NP	damaged tissue	28868
@NP	viable neurons	28894
@NP	numerous small cells	28956
@NP	immune cells	29003
@NP	damaged tissue	29029
@NP	normal-appearing tissue	29071
@NP	numerous neurons , intact white matter and little or no cellular infiltration	29110
@NP	numerous neurons	29110
@NP	intact white matter	29128
@NP	little or no cellular infiltration	29152
@NP	The administration of MP/IL -10	29188
@NP	The administration	29188
@NP	MP/IL -10	29210
@NP	tissue cavitation -LRB- Fig. 1B -RRB-	29241
@NP	tissue cavitation	29241
@NP	Fig. 1B	29260
@NP	animals receiving either SC or SC/OEG grafts	29273
@NP	animals	29273
@NP	SC or SC/OEG grafts	29298
@NP	the grafts	29319
@NP	host spinal tissue	29351
@NP	the presence of only a few	29376
@NP	the presence	29376
@NP	only a few	29392
@NP	small areas	29404
@NP	cavitation	29419
@NP	the interface regions in all transplanted animals -LRB- Fig. 1CÐF -RRB-	29433
@NP	the interface regions	29433
@NP	all transplanted animals -LRB- Fig. 1CÐF -RRB-	29458
@NP	all transplanted animals	29458
@NP	Fig. 1CÐF	29484
@NP	the graft	29504
@NP	neurons	29530
@NP	high numbers of small cells -LRB- transplanted or immune cells -RRB-	29552
@NP	high numbers	29552
@NP	small cells -LRB- transplanted or immune cells -RRB-	29568
@NP	small cells	29568
@NP	transplanted or immune cells	29581
@NP	transplanted	29581
@NP	immune cells	29597
@NP	it	29612
@NP	damaged tissue without immunostaining -LRB- see below -RRB-	29647
@NP	damaged tissue without immunostaining	29647
@NP	damaged tissue	29647
@NP	immunostaining	29670
@NP	the graft	29707
@NP	normal-appearing spinal tissue which contained neurons	29742
@NP	normal-appearing spinal tissue	29742
@NP	neurons	29789
@NP	normal cellular density -LRB- Fig. 2A -RRB-	29829
@NP	normal cellular density	29829
@NP	Fig. 2A	29854
@NP	The volumes of the 9 mm segment of cord and cavitation after each intervention	29864
@NP	The volumes	29864
@NP	the 9 mm segment of cord and cavitation after each intervention	29879
@NP	the 9 mm segment	29879
@NP	cord and cavitation after each intervention	29899
@NP	cord and cavitation	29899
@NP	each intervention	29925
@NP	the uninjured rat	29962
@NP	the volume of the 9 mm segment of T8Ð10 spinal cord	29981
@NP	the volume	29981
@NP	the 9 mm segment of T8Ð10 spinal cord	29995
@NP	the 9 mm segment	29995
@NP	T8Ð10 spinal cord	30015
@NP	28.2 ± 1.2 mm3	30037
@NP	28.2 ±	30037
@NP	1.2 mm3	30044
@NP	injured groups	30056
@NP	a significant diminution of the total volume of the 9 mm cord segment	30072
@NP	a significant diminution	30072
@NP	the total volume of the 9 mm cord segment	30100
@NP	the total volume	30100
@NP	the 9 mm cord segment	30120
@NP	the control	30159
@NP	contused animals , the cord and cavity volumes	30172
@NP	contused animals	30172
@NP	the cord	30190
@NP	cavity volumes	30203
@NP	15.4 ± 1.5 and 6.0 ± 0.7 mm3 , respectively -LRB- Table 1 , Fig. 2B -RRB-	30223
@NP	15.4 ± 1.5 and 6.0 ± 0.7 mm3 , respectively	30223
@NP	15.4	30223
@NP	± 1.5 and 6.0 ± 0.7 mm3	30228
@NP	Table 1	30267
@NP	Fig. 2B	30276
@NP	The percentage	30286
@NP	total cord volume	30304
@NP	comparison	30336
@NP	uninjured 9 mm blocks of spinal cord	30350
@NP	uninjured 9 mm blocks	30350
@NP	9	30360
@NP	spinal cord	30375
@NP	the same region in a similarly-sized rat	30392
@NP	the same region	30392
@NP	a similarly-sized rat	30411
@NP	54.7 ± 5.3 %	30438
@NP	54.7 ±	30438
@NP	the percentage of cavitation volume vs. the total cord volume	30454
@NP	the percentage	30454
@NP	cavitation volume vs. the total cord volume	30472
@NP	cavitation volume	30472
@NP	the total cord volume	30494
@NP	38.8 ± 2.7 % -LRB- Fig. 2C -RRB-	30520
@NP	38.8 ± 2.7 %	30520
@NP	38.8 ±	30520
@NP	2.7 %	30527
@NP	Fig. 2C	30533
@NP	the animals that received MP/IL -10 or SC transplants	30546
@NP	the animals	30546
@NP	MP/IL -10 or SC transplants	30572
@NP	MP/IL -10	30572
@NP	SC transplants	30584
@NP	there	30600
@NP	a significant increase in the total cord volume -LRB- p < 0.01 -RRB-	30610
@NP	a significant increase	30610
@NP	the total cord volume -LRB- p < 0.01 -RRB-	30636
@NP	the total cord volume	30636
@NP	p < 0.01	30659
@NP	p	30659
@NP	< 0.01	30661
@NP	<	30661
@NP	0.01	30663
@NP	a reduction	30673
@NP	the volume of cavitation -LRB- p < 0.001 -RRB- -LRB- Table 1 , Fig. 2B , C -RRB-	30688
@NP	the volume	30688
@NP	cavitation -LRB- p < 0.001 -RRB- -LRB- Table 1 , Fig. 2B , C -RRB-	30702
@NP	cavitation -LRB- p < 0.001 -RRB-	30702
@NP	cavitation	30702
@NP	p < 0.001	30714
@NP	p	30714
@NP	< 0.001	30716
@NP	<	30716
@NP	0.001	30718
@NP	Table 1	30726
@NP	Fig. 2B	30735
@NP	C	30743
@NP	MP/IL -10 at 1 week before SC transplantation	30747
@NP	MP/IL -10	30747
@NP	1 week before SC transplantation	30759
@NP	1 week	30759
@NP	SC transplantation	30773
@NP	the volume of cavitation -LRB- p < 0.05 -RRB-	30808
@NP	the volume	30808
@NP	cavitation -LRB- p < 0.05 -RRB-	30822
@NP	cavitation	30822
@NP	p < 0.05	30834
@NP	p	30834
@NP	< 0.05	30836
@NP	<	30836
@NP	0.05	30838
@NP	SC/OEG grafting into the injury site at 1 week	30845
@NP	SC/OEG grafting	30845
@NP	the injury site at 1 week	30866
@NP	the injury site	30866
@NP	1 week	30885
@NP	the total cord volume	30902
@NP	controls -LRB- p < 0.01 -RRB- and reduced cavitation -LRB- p < 0.001 -RRB-	30929
@NP	controls -LRB- p < 0.01 -RRB-	30929
@NP	controls	30929
@NP	p < 0.01	30939
@NP	p	30939
@NP	< 0.01	30941
@NP	<	30941
@NP	0.01	30943
@NP	reduced cavitation -LRB- p < 0.001 -RRB-	30953
@NP	reduced cavitation	30953
@NP	p < 0.001	30973
@NP	p	30973
@NP	< 0.001	30975
@NP	<	30975
@NP	0.001	30977
@NP	Table 1	30985
@NP	Fig. 2B	30994
@NP	C	31002
@NP	MP/IL -10 with grafting further	31013
@NP	MP/IL -10	31013
@NP	cavitation -LRB- p < 0.05 -RRB-	31052
@NP	cavitation	31052
@NP	p < 0.05	31064
@NP	p	31064
@NP	< 0.05	31066
@NP	<	31066
@NP	0.05	31068
@NP	We	31075
@NP	the amount	31110
@NP	tissue	31132
@NP	tissue that exhibited increased cellular density , myelin disruption	31146
@NP	tissue	31146
@NP	increased cellular density , myelin disruption	31168
@NP	increased cellular density	31168
@NP	myelin disruption	31196
@NP	lack of neurons , as well as normal-appearing tissue	31218
@NP	lack	31218
@NP	neurons , as well as normal-appearing tissue	31226
@NP	neurons	31226
@NP	normal-appearing tissue	31246
@NP	tissue containing neurons	31277
@NP	tissue	31277
@NP	neurons	31295
@NP	intact white matter	31304
@NP	normal cellular density -LRB- Fig. 2A -RRB-	31328
@NP	normal cellular density	31328
@NP	Fig. 2A	31353
@NP	The damaged tissue volume	31363
@NP	a percentage of the total cord volume	31406
@NP	a percentage	31406
@NP	the total cord volume	31422
@NP	the same animal -LRB- Table 1 -RRB-	31449
@NP	the same animal	31449
@NP	Table 1	31466
@NP	The normal-appearing tissue volume	31476
@NP	a percentage of the average total cord volume of uninjured rat spinal cord	31532
@NP	a percentage	31532
@NP	the average total cord volume of uninjured rat spinal cord	31548
@NP	the average total cord volume	31548
@NP	uninjured rat spinal cord	31581
@NP	the transplanted animals damaged	31620
@NP	the transplanted animals	31620
@NP	tissue	31653
@NP	the graft	31692
@NP	damaged tissue volumes for these animals	31703
@NP	damaged tissue volumes	31703
@NP	these animals	31730
@NP	the graft	31771
@NP	the normal-appearing host spinal tissue	31809
@NP	it	31852
@NP	neurons or typical cellular density	31871
@NP	neurons	31871
@NP	typical cellular density	31882
@NP	the control , contused animals	31911
@NP	the control	31911
@NP	contused animals	31924
@NP	the volumes of damaged and normal-appearing tissue	31941
@NP	the volumes	31941
@NP	damaged and normal-appearing tissue	31956
@NP	1.5 6 1.0 mm3 -LRB- 10.0 ± 6.2 % -RRB-	31997
@NP	1.5 6 1.0 mm3	31997
@NP	1.5 6	31997
@NP	1.0 mm3	32003
@NP	10.0 ± 6.2 %	32012
@NP	10.0	32012
@NP	± 6.2 %	32017
@NP	7.9 ± 1.1 mm3 -LRB- 28.0 ± 3.8 % -RRB-	32029
@NP	7.9	32029
@NP	± 1.1 mm3 -LRB- 28.0 ± 3.8 % -RRB-	32033
@NP	± 1.1 mm3	32033
@NP	28.0 ± 3.8 %	32044
@NP	28.0	32044
@NP	± 3.8 %	32049
@NP	Table 1	32072
@NP	Fig. 2D	32081
@NP	the animals that received MP/IL -10	32094
@NP	the animals	32094
@NP	MP/IL -10	32120
@NP	there	32130
@NP	significant increases	32141
@NP	the volumes	32166
@NP	damaged tissue -LRB- p < 0.01 -RRB-	32181
@NP	damaged tissue	32181
@NP	p < 0.01	32197
@NP	p	32197
@NP	< 0.01	32199
@NP	<	32199
@NP	0.01	32201
@NP	normal-appearing tissue -LRB- p < 0.01 -RRB- -LRB- Table 1 -RRB-	32211
@NP	normal-appearing tissue -LRB- p < 0.01 -RRB-	32211
@NP	normal-appearing tissue	32211
@NP	p < 0.01	32236
@NP	p	32236
@NP	< 0.01	32238
@NP	<	32238
@NP	0.01	32240
@NP	Table 1	32247
@NP	Transplantation of SC or SC/OEG grafts	32257
@NP	Transplantation	32257
@NP	SC or SC/OEG grafts	32276
@NP	the amount	32306
@NP	normal-appearing tissue -LRB- p < 0.01 -RRB- -LRB- Table 1 , Fig. 2D -RRB-	32320
@NP	normal-appearing tissue -LRB- p < 0.01 -RRB-	32320
@NP	normal-appearing tissue	32320
@NP	p < 0.01	32345
@NP	p	32345
@NP	< 0.01	32347
@NP	<	32347
@NP	0.01	32349
@NP	Table 1	32356
@NP	Fig. 2D	32365
@NP	Grafting of SCs or SCs/OEG subsequent to MP/IL10 administration	32375
@NP	Grafting	32375
@NP	SCs or SCs/OEG subsequent to MP/IL10 administration	32387
@NP	SCs or SCs/OEG	32387
@NP	MP/IL10 administration	32416
@NP	the volume of normal-appearing tissue	32471
@NP	the volume	32471
@NP	normal-appearing tissue	32485
@NP	MP/IL -10 alone -LRB- p < 0.05 -RRB-	32521
@NP	MP/IL -10 alone	32521
@NP	MP/IL -10	32521
@NP	p < 0.05	32537
@NP	p	32537
@NP	< 0.05	32539
@NP	<	32539
@NP	0.05	32541
@NP	Axons in the Graft and Beyond We	32548
@NP	Axons	32548
@NP	the Graft	32557
@NP	We	32578
@NP	CNS	32586
@NP	nuclei-specific anterograde axon	32590
@NP	the presence of brainstem axons	32642
@NP	the presence	32642
@NP	brainstem axons	32658
@NP	grafts	32677
@NP	each treatment group	32698
@NP	all groups	32723
@NP	corticospinal and vestibulospinal fibers	32735
@NP	grafts even with precedent MP/IL -10 -LRB- Fig. 3A , C -RRB-	32801
@NP	grafts even with precedent MP/IL -10	32801
@NP	grafts	32801
@NP	precedent MP/IL -10	32818
@NP	Fig. 3A , C	32838
@NP	Fig. 3A	32838
@NP	C	32846
@NP	many traced vestibulospinal fibers	32859
@NP	many	32859
@NP	vestibulospinal fibers	32871
@NP	preserved white matter around the injury/graft site	32911
@NP	preserved white matter	32911
@NP	the injury/graft site	32941
@NP	most corticospinal axons	32964
@NP	present rostral	32994
@NP	the grafted area	33013
@NP	axonal end bulbs	33044
@NP	progressive degeneration -LRB- Tator , 1995 -RRB-	33076
@NP	progressive degeneration	33076
@NP	Tator	33102
@NP	1995	33109
@NP	all grafted groups	33119
@NP	all	33119
@NP	groups	33131
@NP	some corticospinal axons	33139
@NP	only small sprouts	33173
@NP	the rostral graft/host interface	33199
@NP	SC only grafts	33236
@NP	SC only	33236
@NP	limited sprouting of reticulospinal fibers	33252
@NP	limited	33252
@NP	reticulospinal fibers	33273
@NP	most of the SC/OEG grafted animals -LRB- three of five -RRB-	33308
@NP	most	33308
@NP	the SC/OEG grafted animals -LRB- three of five -RRB-	33316
@NP	the SC/OEG	33316
@NP	animals -LRB- three of five -RRB-	33335
@NP	animals	33335
@NP	three of five	33344
@NP	three	33344
@NP	five	33353
@NP	a few	33369
@NP	reticulospinal fibers -LRB- ,5 fibers/animal -RRB- ,	33383
@NP	reticulospinal fibers	33383
@NP	,5 fibers/animal	33406
@NP	the center of the graft and an occasional fiber	33448
@NP	the center	33448
@NP	the graft and an occasional fiber	33462
@NP	the graft	33462
@NP	an occasional fiber	33476
@NP	the graft	33503
@NP	a short distance	33517
@NP	the caudal spinal cord	33539
@NP	both these grafted groups	33566
@NP	both these	33566
@NP	groups	33585
@NP	MP/IL -10	33593
@NP	the number	33633
@NP	reticulospinal fibers present at the graft center -LRB- Fig. 3B -RRB-	33647
@NP	reticulospinal fibers present at the graft center	33647
@NP	reticulospinal fibers	33647
@NP	the graft center	33680
@NP	Fig. 3B	33698
@NP	Investigation of serotonergic fiber growth by 5HT immunohistochemistry	33708
@NP	Investigation	33708
@NP	serotonergic fiber growth by 5HT immunohistochemistry	33725
@NP	serotonergic fiber growth	33725
@NP	5HT immunohistochemistry	33754
@NP	these fibers	33791
@NP	both white and gray matter rostral	33820
@NP	the graft site	33858
@NP	Only SC/OEG grafts	33874
@NP	their growth	33901
@NP	the middle of the graft -LRB- 11.3 ± 6.3 fibers/section -RRB-	33919
@NP	the middle	33919
@NP	the graft -LRB- 11.3 ± 6.3 fibers/section -RRB-	33933
@NP	the graft	33933
@NP	11.3 ± 6.3 fibers/section	33944
@NP	11.3 ±	33944
@NP	6.3 fibers/section	33951
@NP	there	33972
@NP	no significant increase	33982
@NP	fibers	34009
@NP	the grafts	34025
@NP	MP/IL -10	34041
@NP	Fig. 4A , B	34073
@NP	Fig. 4A	34073
@NP	B	34081
@NP	The degree of fiber sparing/regeneration caudal to the injury/transplant site	34085
@NP	The degree	34085
@NP	fiber sparing/regeneration caudal to the injury/transplant site	34099
@NP	fiber sparing/regeneration caudal	34099
@NP	the injury/transplant site	34136
@NP	another set	34184
@NP	animals	34199
@NP	injection of the retrograde tracer , Fast Blue , caudal to the injury site	34217
@NP	injection	34217
@NP	the retrograde tracer , Fast Blue , caudal to the injury site	34230
@NP	the retrograde tracer , Fast Blue ,	34230
@NP	the retrograde tracer	34230
@NP	Fast Blue	34253
@NP	the injury site	34274
@NP	neurons in the motor cortex	34299
@NP	neurons	34299
@NP	the motor cortex	34310
@NP	reticular formation and vestibular nucleus	34328
@NP	reticular formation	34328
@NP	vestibular nucleus	34352
@NP	Fig. 5DÐF	34388
@NP	spinal cord injured controls	34403
@NP	spinal cord	34403
@NP	controls	34423
@NP	the estimated total numbers	34433
@NP	labeled neurons in the motor cortex , reticular formation and vestibular nuclei	34464
@NP	labeled neurons	34464
@NP	the motor cortex , reticular formation and vestibular nuclei	34483
@NP	the motor cortex	34483
@NP	reticular formation	34501
@NP	vestibular nuclei	34525
@NP	9.0 ± 3.8 , 3280 ± 560 , and 4370 ± 740 , respectively	34548
@NP	9.0 ± 3.8	34548
@NP	9.0 ±	34548
@NP	3.8	34554
@NP	3280 ± 560	34559
@NP	3280 ±	34559
@NP	560	34566
@NP	4370 ± 740 , respectively	34575
@NP	4370 ±	34575
@NP	740	34582
@NP	No significant change	34601
@NP	the number of labeled neurons in the motor cortex and vestibular nuclei	34626
@NP	the number	34626
@NP	labeled neurons in the motor cortex and vestibular nuclei	34640
@NP	neurons in the motor cortex	34648
@NP	neurons	34648
@NP	the motor cortex	34659
@NP	all treatment groups -LRB- Fig. 5D-F -RRB-	34714
@NP	all treatment groups	34714
@NP	Fig. 5D-F	34736
@NP	the other hand , MP/IL -10 or SC/OEG grafts	34751
@NP	the other hand	34751
@NP	MP/IL -10	34767
@NP	SC/OEG grafts	34779
@NP	regeneration	34812
@NP	fibers	34828
@NP	the reticular formation	34840
@NP	an increase	34875
@NP	Fast Blue	34890
@NP	neurons	34908
@NP	5220 ± 1290 -LRB- p < 0.05 -RRB- and 5790 ± 1340 -LRB- p < 0.01 -RRB-	34917
@NP	5220 ± 1290 -LRB- p < 0.05 -RRB-	34917
@NP	5220 ± 1290	34917
@NP	p < 0.05	34930
@NP	p	34930
@NP	< 0.05	34932
@NP	<	34932
@NP	0.05	34934
@NP	5790 ± 1340 -LRB- p < 0.01 -RRB-	34944
@NP	5790 ± 1340	34944
@NP	p < 0.01	34957
@NP	p	34957
@NP	< 0.01	34959
@NP	<	34959
@NP	0.01	34961
@NP	Fig. 5E	34982
@NP	The combination of MP/IL -10 with later SC/OEG grafting	34992
@NP	The combination	34992
@NP	MP/IL -10 with later SC/OEG grafting	35011
@NP	MP/IL -10	35011
@NP	later SC/OEG grafting	35025
@NP	reticulospinal fiber sparing/regeneration	35073
@NP	Modification of Host Cord	35116
@NP	Modification	35116
@NP	Host Cord	35132
@NP	Astroglial Reactivity	35142
@NP	We	35164
@NP	the degree	35176
@NP	host spinal cord scarring rostral and caudal to the injury/transplantation site	35190
@NP	host spinal cord scarring rostral	35190
@NP	host	35190
@NP	spinal cord scarring rostral	35195
@NP	caudal to the injury/transplantation site	35228
@NP	caudal	35228
@NP	the injury/transplantation site	35238
@NP	the intensity of GFAP immunoreactivity	35283
@NP	the intensity	35283
@NP	GFAP immunoreactivity	35300
@NP	Fig. 6	35323
@NP	injured control animals	35335
@NP	the intensity	35360
@NP	GFAP rostral and caudal to the injury epicenter	35377
@NP	GFAP rostral and caudal	35377
@NP	the injury epicenter	35404
@NP	arbitrary units	35438
@NP	85.65 ± 14.32 and 110.27 ± 11.69 , respectively -LRB- Fig. 6B -RRB-	35459
@NP	85.65 ± 14.32 and 110.27 ± 11.69 , respectively	35459
@NP	85.65 ± 14.32 and 110.27 ± 11.69	35459
@NP	85.65	35459
@NP	± 14.32 and 110.27 ± 11.69	35465
@NP	Fig. 6B	35507
@NP	GFAP immunoreactivity	35517
@NP	the injury site	35558
@NP	tissue bridges	35585
@NP	A significant reduction in GFAP intensity	35601
@NP	A significant reduction	35601
@NP	GFAP intensity	35628
@NP	the injury epicenter , 76.84 ± 12.09 -LRB- p < 0.05 -RRB-	35666
@NP	the injury epicenter	35666
@NP	76.84 ± 12.09 -LRB- p < 0.05 -RRB-	35688
@NP	76.84	35688
@NP	± 12.09 -LRB- p < 0.05 -RRB-	35694
@NP	± 12.09	35694
@NP	p < 0.05	35703
@NP	p	35703
@NP	< 0.05	35705
@NP	<	35705
@NP	0.05	35707
@NP	rostral	35722
@NP	MP/IL -10 administration	35741
@NP	contrast	35775
@NP	grafting of SCs	35785
@NP	grafting	35785
@NP	SCs	35797
@NP	GFAP immunoreactivity both rostrally -LRB- 159.05 ± 18.01 ; p < 0.01 -RRB-	35825
@NP	GFAP immunoreactivity both rostrally	35825
@NP	GFAP immunoreactivity both	35825
@NP	GFAP immunoreactivity	35825
@NP	159.05 ± 18.01 ; p < 0.01	35863
@NP	159.05 ± 18.01 ; p <	35863
@NP	159.05 ± 18.01	35863
@NP	159.05 ±	35863
@NP	18.01	35872
@NP	p <	35879
@NP	p	35879
@NP	<	35881
@NP	0.01	35883
@NP	192.34 ± 19.09 ; p < 0.01	35903
@NP	192.34 ± 19.09 ; p <	35903
@NP	192.34 ± 19.09	35903
@NP	192.34 ±	35903
@NP	19.09	35912
@NP	p <	35919
@NP	p	35919
@NP	<	35921
@NP	0.01	35923
@NP	injury-only controls	35941
@NP	Animals with SC grafts	35963
@NP	Animals	35963
@NP	SC grafts	35976
@NP	an intense area	35996
@NP	GFAP immunoreactive astrocytes surrounding the graft/injury site	36015
@NP	GFAP immunoreactive astrocytes	36015
@NP	the graft/injury site	36058
@NP	very few GFAP1 cells	36084
@NP	the grafts	36123
@NP	The intensity of GFAP immunoreactivity rostral and caudal to SC/OEG grafts	36135
@NP	The intensity	36135
@NP	GFAP immunoreactivity rostral and caudal to SC/OEG grafts	36152
@NP	GFAP immunoreactivity rostral	36152
@NP	caudal to SC/OEG grafts	36186
@NP	caudal	36186
@NP	SC/OEG grafts	36196
@NP	Fig. 6B	36239
@NP	the prior administration of MP/IL -10	36258
@NP	the prior administration	36258
@NP	MP/IL -10	36286
@NP	GFAP intensity	36303
@NP	17.5 % -LRB- p < 0.05 -RRB- in the caudal spinal cord	36321
@NP	17.5 % -LRB- p < 0.05 -RRB-	36321
@NP	17.5 %	36321
@NP	p < 0.05	36328
@NP	p	36328
@NP	< 0.05	36330
@NP	<	36330
@NP	0.05	36332
@NP	the caudal spinal cord	36341
@NP	SC grafting	36370
@NP	Functional Recovery	36383
@NP	All animals	36403
@NP	hindlimb function	36435
@NP	the first 2Ð3 weeks post-transplantation and then more	36456
@NP	the first 2Ð3 weeks	36456
@NP	a plateau	36529
@NP	the next 5-6 weeks -LRB- Fig. 7A -RRB-	36544
@NP	the next 5-6 weeks	36544
@NP	Fig. 7A	36564
@NP	the group that received no treatment after contusion	36577
@NP	the group	36577
@NP	no treatment	36601
@NP	contusion	36620
@NP	the rats	36631
@NP	a stage at 8 weeks	36653
@NP	a stage	36653
@NP	8 weeks	36664
@NP	they	36678
@NP	occasional	36693
@NP	frequent weight-supported plantar steps	36707
@NP	little hindlimb-forelimb -LRB- HL-FL -RRB- coordination	36761
@NP	little hindlimb-forelimb -LRB- HL-FL -RRB-	36761
@NP	little hindlimb-forelimb	36761
@NP	HL-FL	36787
@NP	BBB , 10.6 ± 1.1	36808
@NP	BBB	36808
@NP	10.6 ± 1.1	36813
@NP	10.6 ±	36813
@NP	1.1	36820
@NP	injury only controls	36838
@NP	injury only	36838
@NP	a significant improvement in motor performance -LRB- p < 0.05 -RRB-	36860
@NP	a significant improvement in motor performance	36860
@NP	a significant improvement	36860
@NP	motor performance	36889
@NP	p < 0.05	36908
@NP	p	36908
@NP	< 0.05	36910
@NP	<	36910
@NP	0.05	36912
@NP	the combination of SC/OEG grafting and acute MP/IL -10	36937
@NP	the combination	36937
@NP	SC/OEG grafting and acute MP/IL -10	36956
@NP	SC/OEG grafting	36956
@NP	acute MP/IL -10	36976
@NP	These animals	36992
@NP	consistent plantar	37016
@NP	occasional to frequent coordination	37049
@NP	occasional	37049
@NP	frequent coordination	37063
@NP	BBB , 12.7 ± 0.4	37086
@NP	BBB	37086
@NP	12.7 ± 0.4	37091
@NP	12.7 ±	37091
@NP	0.4	37098
@NP	The employment of a subscore for the BBB score	37104
@NP	The employment	37104
@NP	a subscore for the BBB score	37122
@NP	a subscore	37122
@NP	the BBB score	37137
@NP	us	37159
@NP	the presence of certain features	37173
@NP	the presence	37173
@NP	certain features	37189
@NP	score 14Ñe	37212
@NP	g. , foot placement , toe clearance , and tail position Ñthat	37223
@NP	g.	37223
@NP	foot placement	37227
@NP	toe clearance	37243
@NP	tail position Ñthat	37262
@NP	a different order	37300
@NP	the BBB scale -LRB- scored on a 0-13-point scale -RRB-	37326
@NP	the BBB scale	37326
@NP	a 0-13-point scale	37351
@NP	a BBB subscore of 3 ± 1.9 at 8 weeks -LRB- Fig. 7B -RRB-	37403
@NP	a BBB subscore	37403
@NP	3 ± 1.9 at 8 weeks -LRB- Fig. 7B -RRB-	37421
@NP	3 ± 1.9 at 8 weeks	37421
@NP	3 ±	37421
@NP	1.9 at 8 weeks	37425
@NP	Fig. 7B	37441
@NP	Animals	37451
@NP	SC/OEG	37472
@NP	prior MP/IL	37496
@NP	-10 administration	37507
@NP	significantly higher BBB subscores	37534
@NP	more features -LRB- BBB score of .14 -RRB-	37586
@NP	more features	37586
@NP	BBB score of .14	37601
@NP	BBB score	37601
@NP	.14	37614
@NP	week 3 to 8	37624
@NP	the injured-only controls	37648
@NP	scores at endpoint	37680
@NP	scores	37680
@NP	endpoint	37690
@NP	7.3 ± 0.5 -LRB- p < 0.01 -RRB- and 7.2 ± 1.3 -LRB- p < 0.01 -RRB- , respectively	37705
@NP	7.3 ± 0.5 -LRB- p < 0.01 -RRB- and 7.2 ± 1.3 -LRB- p < 0.01 -RRB-	37705
@NP	7.3 ± 0.5 -LRB- p < 0.01 -RRB-	37705
@NP	7.3 ± 0.5	37705
@NP	p < 0.01	37716
@NP	p	37716
@NP	< 0.01	37718
@NP	<	37718
@NP	0.01	37720
@NP	7.2 ± 1.3 -LRB- p < 0.01 -RRB-	37730
@NP	7.2	37730
@NP	± 1.3 -LRB- p < 0.01 -RRB-	37734
@NP	± 1.3	37734
@NP	p < 0.01	37741
@NP	p	37741
@NP	< 0.01	37743
@NP	<	37743
@NP	0.01	37745
@NP	No significant difference	37766
@NP	SC/OEG-only and SC/OEG 1 MP/IL -10 groups	37809
@NP	SC/OEG-only	37809
@NP	SC/OEG 1 MP/IL -10 groups	37825
@NP	SC/OEG 1 MP/IL	37825
@NP	-10 groups	37839
@NP	Footprint analysis of the hindlimbs	37851
@NP	Footprint analysis	37851
@NP	the hindlimbs	37873
@NP	8 weeks	37904
@NP	Analysis of uninjured animals	37913
@NP	Analysis	37913
@NP	uninjured animals	37925
@NP	a mean angle of rotation of the hindlimbs of 12.9 ± 0.9 ° -LRB- Fig. 8A -RRB-	37952
@NP	a mean angle	37952
@NP	rotation of the hindlimbs of 12.9 ± 0.9 ° -LRB- Fig. 8A -RRB-	37968
@NP	rotation	37968
@NP	the hindlimbs of 12.9 ± 0.9 ° -LRB- Fig. 8A -RRB-	37980
@NP	the hindlimbs	37980
@NP	12.9 ± 0.9 ° -LRB- Fig. 8A -RRB-	37997
@NP	12.9 ± 0.9 °	37997
@NP	12.9 ±	37997
@NP	0.9 °	38004
@NP	Fig. 8A	38010
@NP	injury	38026
@NP	this parameter	38033
@NP	a mean	38061
@NP	30.4	38071
@NP	± 2.3 °	38076
@NP	animals that received SCs	38087
@NP	animals	38087
@NP	SCs	38109
@NP	foot exo-rotation	38114
@NP	25.7 ±	38159
@NP	1.7 ° -LRB- p < 0.05 -RRB-	38166
@NP	1.7 °	38166
@NP	p < 0.05	38172
@NP	p	38172
@NP	< 0.05	38174
@NP	<	38174
@NP	0.05	38176
@NP	administration of MP/IL -10	38189
@NP	administration	38189
@NP	MP/IL -10	38207
@NP	SC transplantation	38223
@NP	this benefit -LRB- p < 0.001 -RRB-	38276
@NP	this benefit	38276
@NP	p < 0.001	38290
@NP	p	38290
@NP	< 0.001	38292
@NP	<	38292
@NP	0.001	38294
@NP	foot exo-rotation	38333
@NP	injured-only controls , 36.6 ± 1.9 ° -LRB- p < 0.01 -RRB-	38363
@NP	injured-only controls	38363
@NP	36.6 ± 1.9 ° -LRB- p < 0.01 -RRB-	38386
@NP	36.6 ± 1.9 °	38386
@NP	36.6 ±	38386
@NP	1.9 °	38393
@NP	p < 0.01	38399
@NP	p	38399
@NP	< 0.01	38401
@NP	<	38401
@NP	0.01	38403
@NP	The base	38410
@NP	support	38422
@NP	the distance between the left and right hind paw central pads	38445
@NP	the distance	38445
@NP	the left and right hind paw central pads	38466
@NP	the left and right hind paw	38466
@NP	central pads	38494
@NP	any treatment	38530
@NP	The combination of MP/IL	38545
@NP	The combination	38545
@NP	MP/IL	38564
@NP	10 with SC transplantation significantly worsened the base of support	38571
@NP	10	38571
@NP	SC transplantation significantly worsened the base of support	38579
@NP	SC transplantation	38579
@NP	the base of support	38621
@NP	the base	38621
@NP	support	38633
@NP	trunk instability	38658
@NP	5.0 ±	38677
@NP	0.6 cm -LRB- p < 0.05 -RRB- , injured-only con	38700
@NP	0.6 cm -LRB- p < 0.05 -RRB-	38700
@NP	p < 0.05	38708
@NP	p	38708
@NP	< 0.05	38710
@NP	<	38710
@NP	0.05	38712
@NP	injured-only con	38719
@NP	trols -RSB- -LRB- Fig. 8B -RRB-	38737
@NP	trols	38737
@NP	-RSB- -LRB- Fig. 8B -RRB-	38742
@NP	-RSB-	38742
@NP	Fig. 8B	38745
@NP	Stride length	38755
@NP	injury -LRB- Fig. 8C -RRB-	38804
@NP	injury	38804
@NP	Fig. 8C	38812
@NP	a grid with randomly	38843
@NP	a grid	38843
@NP	bars	38871
@NP	the number of footfall errors	38901
@NP	the number	38901
@NP	footfall errors	38915
@NP	bars	38939
@NP	each hindlimb	38953
@NP	uninjured animals	38971
@NP	the mean error rate in hindlimb footfalls	38990
@NP	the mean error rate	38990
@NP	hindlimb footfalls	39013
@NP	0.7 ± 0.5	39036
@NP	0.7	39036
@NP	± 0.5	39040
@NP	8 weeks after injury	39050
@NP	8 weeks	39050
@NP	injury	39064
@NP	animals	39072
@NP	a mean error rate of 15.1 ± 1.5 -LRB- Fig. 8D -RRB-	39090
@NP	a mean error rate	39090
@NP	15.1 ± 1.5 -LRB- Fig. 8D -RRB-	39111
@NP	15.1 ± 1.5	39111
@NP	Fig. 8D	39123
@NP	the interventions	39136
@NP	only the acute administration of MP/IL -10 by itself	39155
@NP	only the acute administration	39155
@NP	MP/IL -10 by itself	39188
@NP	MP/IL -10	39188
@NP	itself	39200
@NP	the number of footfall errors	39229
@NP	the number	39229
@NP	footfall errors	39243
@NP	the gridwalk	39262
@NP	10.5 ± 1.9 -LRB- p < 0.05 -RRB-	39279
@NP	10.5 ± 1.9	39279
@NP	p < 0.05	39291
@NP	p	39291
@NP	< 0.05	39293
@NP	<	39293
@NP	0.05	39295
@NP	contrast	39305
@NP	prior administration of MP/IL -10	39315
@NP	prior administration	39315
@NP	MP/IL -10	39339
@NP	the performance of SC transplanted animals	39371
@NP	the performance	39371
@NP	SC transplanted animals	39390
@NP	the gridwalk	39417
@NP	SC-only animals , 17.1 ± 1.0 versus 13.1 ± 2.5 -LRB- p < 0.05 -RRB-	39442
@NP	SC-only animals	39442
@NP	17.1 ± 1.0 versus 13.1 ± 2.5 -LRB- p < 0.05 -RRB-	39459
@NP	17.1 ± 1.0	39459
@NP	13.1 ± 2.5 -LRB- p < 0.05 -RRB-	39477
@NP	13.1 ± 2.5	39477
@NP	p < 0.05	39489
@NP	p	39489
@NP	< 0.05	39491
@NP	<	39491
@NP	0.05	39493
@NP	DISCUSSION Administration of either MP/IL -10 or SC or SC/OEG transplantation	39501
@NP	DISCUSSION Administration	39501
@NP	either MP/IL -10 or SC or SC/OEG transplantation	39530
@NP	MP/IL -10	39537
@NP	SC or SC/OEG transplantation	39549
@NP	moderate contusive SCI of rat thoracic spinal cord	39585
@NP	moderate contusive SCI	39585
@NP	rat thoracic spinal cord	39611
@NP	the volume of normal-appearing tissue 12 weeks post-injury	39661
@NP	the volume	39661
@NP	normal-appearing tissue 12 weeks post-injury	39675
@NP	normal-appearing tissue	39675
@NP	12 weeks	39699
@NP	The combination of either cell transplantation strategy	39721
@NP	The combination	39721
@NP	either cell transplantation strategy	39740
@NP	MP/IL -10	39782
@NP	further reduced cavitation volume compared to single strategies but combinations	39791
@NP	further reduced cavitation volume	39791
@NP	single strategies but combinations	39837
@NP	single strategies	39837
@NP	combinations	39859
@NP	normal-appearing tissue as MP/IL -10	39908
@NP	normal-appearing tissue	39908
@NP	MP/IL -10	39935
@NP	none of the individual treatment strategies	39959
@NP	none	39959
@NP	the individual treatment strategies	39967
@NP	a significant improvement	40015
@NP	gross locomotor performance	40044
@NP	the combination of MP/IL -10 with later SC/OEG transplants	40073
@NP	the combination	40073
@NP	MP/IL -10 with later SC/OEG transplants	40092
@NP	MP/IL -10	40092
@NP	later SC/OEG transplants	40106
@NP	the BBB score	40154
@NP	injury-only controls	40173
@NP	MP/IL	40199
@NP	-10 addition	40204
@NP	SC-only transplants	40226
@NP	behavioral outcome	40264
@NP	Some significant improvements in fine motor control	40284
@NP	Some significant improvements	40284
@NP	fine motor control	40317
@NP	individual treatments	40354
@NP	A summary of these findings	40377
@NP	A summary	40377
@NP	these findings	40390
@NP	Table 2	40421
@NP	the current study	40433
@NP	both the protective and cell transplantation strategies	40452
@NP	the protective	40457
@NP	cell transplantation strategies	40476
@NP	cavitation	40516
@NP	the volume of normal-appearing tissue	40541
@NP	the volume	40541
@NP	normal-appearing tissue	40555
@NP	injuryonly controls	40593
@NP	Our results	40614
@NP	earlier findings of a decrease in cavitation	40634
@NP	earlier findings	40634
@NP	a decrease in cavitation	40654
@NP	a decrease	40654
@NP	cavitation	40668
@NP	SCI	40685
@NP	MP	40694
@NP	Green	40698
@NP	et al. , 1980	40704
@NP	et al.	40704
@NP	1980	40712
@NP	Behrmann et al. , 1994	40718
@NP	Behrmann	40718
@NP	et al. , 1994	40727
@NP	et al.	40727
@NP	1994	40735
@NP	Chen et al. , 1996	40741
@NP	Chen	40741
@NP	et al. , 1996	40746
@NP	et al.	40746
@NP	1996	40754
@NP	Oudega et al. , 1999	40760
@NP	Oudega	40760
@NP	et al. , 1999	40767
@NP	et al.	40767
@NP	1999	40775
@NP	IL-10 -LRB- Bethea et al. , 1999 -RRB-	40782
@NP	IL-10	40782
@NP	Bethea	40789
@NP	et al. , 1999	40796
@NP	et al.	40796
@NP	1999	40804
@NP	MP and IL-10 -LRB- Takami et al. , 2002a -RRB-	40811
@NP	MP and IL-10	40811
@NP	Takami	40825
@NP	et al. , 2002a	40832
@NP	et al.	40832
@NP	2002a	40840
@NP	SC/OEG transplants -LRB- Takami et al. , 2002b -RRB-	40850
@NP	SC/OEG transplants	40850
@NP	Takami	40870
@NP	et al. , 2002b	40877
@NP	et al.	40877
@NP	2002b	40885
@NP	The degree of normal-appearing tissue preservation	40893
@NP	The degree	40893
@NP	normal-appearing tissue preservation	40907
@NP	treatment strategies	40975
@NP	animals receiving MP/IL -10	40997
@NP	animals	40997
@NP	MP/IL -10	41015
@NP	a significantly greater volume of normal-appearing tissue	41037
@NP	a significantly greater volume	41037
@NP	normal-appearing tissue	41071
@NP	those given cell grafts	41100
@NP	This	41125
@NP	the difference	41155
@NP	the timing of the two strategies	41173
@NP	the timing	41173
@NP	the two strategies	41187
@NP	15 minutes versus 1 week , respectively	41207
@NP	15 minutes	41207
@NP	1 week , respectively	41225
@NP	1 week	41225
@NP	the different tissue damaging processes	41251
@NP	the different tissue	41251
@NP	damaging processes	41272
@NP	they	41296
@NP	The acute protective regimen of MP/IL -10	41309
@NP	The acute protective regimen	41309
@NP	MP/IL -10	41341
@NP	the peak of secondary tissue damage	41374
@NP	the peak	41374
@NP	secondary tissue damage	41386
@NP	cell transplantation	41418
@NP	a time when considerable secondary tissue loss had already occurred	41452
@NP	a time	41452
@NP	considerable secondary tissue loss	41464
@NP	Both MP and IL-10	41521
@NP	anti-inflammatory actions	41544
@NP	the acute inflammatory response	41584
@NP	SCI	41622
@NP	MP	41627
@NP	oxygen	41645
@NP	radical-induced lipid peroxidation	41652
@NP	Anderson	41688
@NP	et al. , 1985 ; Koc et al. , 1999	41697
@NP	et al.	41697
@NP	1985 ; Koc et al.	41705
@NP	1985	41705
@NP	Koc et al.	41711
@NP	Koc	41711
@NP	et al.	41715
@NP	1999	41723
@NP	spinal cord blood flow -LRB- Young and Flamm , 1982 ; Hall et al. , 1984 -RRB-	41740
@NP	spinal cord blood flow	41740
@NP	Young and Flamm	41764
@NP	Young	41764
@NP	Flamm	41774
@NP	1982 ; Hall et al. , 1984	41781
@NP	1982	41781
@NP	Hall et al. , 1984	41787
@NP	Hall	41787
@NP	et al. , 1984	41792
@NP	et al.	41792
@NP	1984	41800
@NP	aerobic energy metabolism -LRB- Braughler and Hall , 1983 ; 1984 -RRB-	41817
@NP	aerobic energy metabolism	41817
@NP	Braughler and Hall , 1983 ; 1984	41844
@NP	Braughler and Hall	41844
@NP	1983 ; 1984	41864
@NP	intracellular Ca21 accumulation -LRB- Young and Flamm , 1982 -RRB-	41889
@NP	intracellular Ca21 accumulation	41889
@NP	Young and Flamm , 1982	41922
@NP	Young	41922
@NP	Flamm , 1982	41932
@NP	Flamm	41932
@NP	1982	41939
@NP	actions	41946
@NP	tissue	41988
@NP	the acute phase of the injury	42002
@NP	the acute phase	42002
@NP	the injury	42021
@NP	contrast	42036
@NP	tissue protection mediated by SC or OEG grafts	42046
@NP	tissue protection	42046
@NP	SC or OEG grafts	42076
@NP	a result	42108
@NP	their	42120
@NP	factors	42135
@NP	axonal regeneration	42169
@NP	trophic support	42206
@NP	survival of the injured host cells	42241
@NP	survival	42241
@NP	the injured host cells	42253
@NP	SCs	42277
@NP	a variety	42289
@NP	growth factors	42302
@NP	neuronal survival	42356
@NP	nerve growth factor -LRB- Bandtlow et al. , 1987 -RRB-	42385
@NP	nerve growth factor	42385
@NP	Bandtlow	42406
@NP	et al. , 1987	42415
@NP	et al.	42415
@NP	1987	42423
@NP	brainderived neurotrophic factor -LRB- Meyer et al. , 1992 -RRB-	42430
@NP	brainderived neurotrophic factor	42430
@NP	Meyer	42464
@NP	et al. , 1992	42470
@NP	et al.	42470
@NP	1992	42478
@NP	ciliary neurotrophic factor	42485
@NP	Friedman	42514
@NP	et al. , 1992 ; Rende et al. , 1992	42523
@NP	et al.	42523
@NP	1992 ; Rende et al.	42531
@NP	1992	42531
@NP	Rende et al.	42537
@NP	Rende	42537
@NP	et al.	42543
@NP	1992	42551
@NP	glial cell lineÐderived neurotrophic factor -LRB- Widenfalk et al. , 2001 -RRB-	42562
@NP	glial cell	42562
@NP	lineÐderived neurotrophic factor -LRB- Widenfalk et al. , 2001 -RRB-	42573
@NP	lineÐderived neurotrophic factor	42573
@NP	Widenfalk	42607
@NP	et al. , 2001	42617
@NP	et al.	42617
@NP	2001	42625
@NP	Many of these neurotrophic factors	42632
@NP	Many	42632
@NP	these neurotrophic factors	42640
@NP	OEG -LRB- Boruch et al. , 2001 ; Woodhall et al. , 2001 -RRB-	42688
@NP	OEG	42688
@NP	Boruch	42693
@NP	et al. , 2001 ; Woodhall et al. , 2001	42700
@NP	et al.	42700
@NP	2001 ; Woodhall et al.	42708
@NP	2001	42708
@NP	Woodhall et al.	42714
@NP	Woodhall	42714
@NP	et al.	42723
@NP	2001	42731
@NP	Grafting of cells	42738
@NP	Grafting	42738
@NP	cells	42750
@NP	stabilization of the injury site	42772
@NP	stabilization	42772
@NP	the injury site	42789
@NP	lost tissue volume	42816
@NP	secondary tissue damage	42850
@NP	mechanical aggravation of the cyst	42877
@NP	mechanical aggravation	42877
@NP	the cyst	42903
@NP	the later phase of the injury	42919
@NP	the later phase	42919
@NP	the injury	42938
@NP	It	42950
@NP	these different mechanisms	42967
@NP	a combination	42999
@NP	an acute tissue sparing intervention and later cellular grafting	43016
@NP	an acute tissue	43016
@NP	intervention and later cellular grafting	43040
@NP	intervention	43040
@NP	later cellular grafting	43057
@NP	tissue preservation over either treatment alone	43116
@NP	tissue preservation	43116
@NP	either treatment alone	43141
@NP	a significant , two-fold reduction in the volume of cavitation	43174
@NP	a significant , two-fold reduction	43174
@NP	the volume of cavitation	43211
@NP	the volume	43211
@NP	cavitation	43225
@NP	either combination over the individual strategies	43254
@NP	either combination	43254
@NP	the individual strategies	43278
@NP	cell grafting subsequent to MP/IL10	43305
@NP	cell grafting	43305
@NP	MP/IL10	43333
@NP	the volume of normal-appearing tissue	43363
@NP	the volume	43363
@NP	normal-appearing tissue	43377
@NP	MP/IL10 alone	43413
@NP	Reductions in the volume of normal-appearing tissue	43428
@NP	Reductions	43428
@NP	the volume of normal-appearing tissue	43442
@NP	the volume	43442
@NP	normal-appearing tissue	43456
@NP	a result	43501
@NP	the invasive procedure of cell grafting	43513
@NP	the invasive procedure	43513
@NP	cell grafting	43539
@NP	previously protected tissue	43576
@NP	the initiation	43612
@NP	a second , albeit smaller , cascade of injury-associated processes	43630
@NP	a second , albeit smaller , cascade	43630
@NP	injury-associated processes	43667
@NP	the current study	43721
@NP	the transplantation field in general	43745
@NP	the transplantation field	43745
@NP	general	43774
@NP	it	43783
@NP	the introduction of exogenous cells into the injured spinal cord	43809
@NP	the introduction	43809
@NP	exogenous cells into the injured spinal cord	43829
@NP	exogenous cells	43829
@NP	the injured spinal cord	43850
@NP	an inflammatory response	43887
@NP	This response	43913
@NP	either the invasive surgical procedure	43930
@NP	the grafted cells , could in turn	43975
@NP	the grafted cells	43975
@NP	turn	44003
@NP	tissue damage	44019
@NP	secondary injury associated with the cell transplantation procedure	44055
@NP	secondary injury	44055
@NP	the cell transplantation procedure	44088
@NP	it	44124
@NP	the tissue protectants	44158
@NP	others -LRB- Chen et al. , 1996 ; Nash et al. , 2002 -RRB-	44219
@NP	others	44219
@NP	Chen	44227
@NP	et al. , 1996 ; Nash et al. , 2002	44232
@NP	et al.	44232
@NP	1996 ; Nash et al.	44240
@NP	1996	44240
@NP	Nash et al.	44246
@NP	Nash	44246
@NP	et al.	44251
@NP	2002	44259
@NP	We	44266
@NP	more specifically axonal sparing	44283
@NP	a retrograde tracer caudal	44331
@NP	the injury/transplant site	44361
@NP	neurons	44412
@NP	specific brain regions	44423
@NP	fibers	44461
@NP	the injury/transplant site	44475
@NP	the tracer	44532
@NP	the motor cortex and vestibular nuclei	44547
@NP	the motor cortex	44547
@NP	vestibular nuclei	44568
@NP	no change in the number of labeled neurons	44587
@NP	no change	44587
@NP	the number of labeled neurons	44600
@NP	the number	44600
@NP	labeled neurons	44614
@NP	all treatments	44646
@NP	injured-only controls	44673
@NP	Administration of MP/IL -10	44696
@NP	Administration	44696
@NP	MP/IL -10	44714
@NP	the number of retrogradely-labeled neurons	44757
@NP	the number	44757
@NP	retrogradely-labeled neurons	44771
@NP	the reticular formation -LRB- by 59 % -RRB-	44803
@NP	the reticular formation	44803
@NP	59 %	44831
@NP	SC/OEG transplantation -LRB- 86 % -RRB-	44844
@NP	SC/OEG transplantation	44844
@NP	86 %	44868
@NP	The reticular formation	44874
@NP	an important brainstem region	44919
@NP	the initiation	44961
@NP	, inter-limb coordination and posturing	44987
@NP	, inter-limb coordination	44987
@NP	posturing	45017
@NP	gait modifications	45034
@NP	the cat -LRB- Whelan , 1996 ; Prentice and Drew , 2001 -RRB-	45056
@NP	the cat	45056
@NP	Whelan , 1996 ; Prentice and Drew , 2001	45065
@NP	Whelan	45065
@NP	1996 ; Prentice and Drew	45073
@NP	1996	45073
@NP	Prentice and Drew	45079
@NP	2001	45098
@NP	No additional increase in the numbers of labeled neurons	45105
@NP	No additional increase	45105
@NP	the numbers of labeled neurons	45131
@NP	the numbers	45131
@NP	labeled neurons	45146
@NP	the combination of MP/IL -10	45176
@NP	the combination	45176
@NP	MP/IL -10	45195
@NP	cell transplantation paradigm	45216
@NP	We	45247
@NP	MP/IL -10	45267
@NP	the environment of the injured spinal cord	45285
@NP	the environment	45285
@NP	the injured spinal cord	45304
@NP	the regenerative response of damaged axons to grow across SC or SC/OEG grafts	45339
@NP	the regenerative response	45339
@NP	damaged axons to grow across SC or SC/OEG grafts	45368
@NP	SC or SC/OEG grafts	45397
@NP	supraspinal fibers	45426
@NP	SC/OEG grafts	45453
@NP	very few	45468
@NP	SC grafts	45494
@NP	this response	45508
@NP	an earlier protective treatment with MP/IL -10	45539
@NP	an earlier protective treatment	45539
@NP	MP/IL -10	45576
@NP	It	45586
@NP	MP	45620
@NP	dieback of vestibulospinal axons -LRB- Oudega et al. , 1999 -RRB-	45634
@NP	dieback	45634
@NP	vestibulospinal axons -LRB- Oudega et al. , 1999 -RRB-	45645
@NP	vestibulospinal axons	45645
@NP	Oudega	45668
@NP	et al. , 1999	45675
@NP	et al.	45675
@NP	1999	45683
@NP	the distance of corticospinal tract regeneration	45699
@NP	the distance	45699
@NP	corticospinal tract regeneration	45715
@NP	a cervical lesion grafted with OEG -LRB- Nash et al. , 2002 -RRB-	45755
@NP	a cervical lesion	45755
@NP	OEG -LRB- Nash et al. , 2002 -RRB-	45786
@NP	OEG	45786
@NP	Nash	45791
@NP	et al. , 2002	45796
@NP	et al.	45796
@NP	2002	45804
@NP	axonal growth	45822
@NP	a SC cell bridge	45841
@NP	the completely transected rat spinal cord -LRB- Chen et al. , 1996 -RRB-	45874
@NP	the	45874
@NP	rat spinal cord -LRB- Chen et al. , 1996 -RRB-	45900
@NP	rat spinal cord	45900
@NP	Chen	45917
@NP	et al. , 1996	45922
@NP	et al.	45922
@NP	1996	45930
@NP	No direct effect of IL-10 on axon growth	45937
@NP	No direct effect	45937
@NP	IL-10 on axon growth	45957
@NP	IL-10	45957
@NP	axon growth	45966
@NP	The administration of MP/IL -10 in the current experiment	46005
@NP	The administration	46005
@NP	MP/IL -10 in the current experiment	46027
@NP	MP/IL -10	46027
@NP	the current experiment	46039
@NP	the amount of astrogliosis -LRB- GFAP immunoreactivity -RRB-	46084
@NP	the amount	46084
@NP	astrogliosis	46098
@NP	GFAP immunoreactivity	46112
@NP	caudal	46135
@NP	the injury and par	46145
@NP	the increase	46179
@NP	astrogliosis seen in response to SC-only grafting	46195
@NP	astrogliosis	46195
@NP	response	46216
@NP	SC-only grafting	46228
@NP	Astrogliosis	46246
@NP	the subsequent production	46263
@NP	axon growth inhibitory extracellular matrix molecules by reactive astrocytes	46292
@NP	axon growth inhibitory extracellular matrix molecules	46292
@NP	reactive astrocytes	46349
@NP	chondroitin sulfate proteoglycans -LRB- Canning et al. , 1996 -RRB-	46378
@NP	chondroitin sulfate proteoglycans	46378
@NP	Canning	46413
@NP	et al. , 1996	46421
@NP	et al.	46421
@NP	1996	46429
@NP	a significant impediment to regeneration	46440
@NP	a significant impediment	46440
@NP	regeneration	46468
@NP	SCI -LRB- Bradbury et al. , 2002 -RRB-	46487
@NP	SCI	46487
@NP	Bradbury	46492
@NP	et al. , 2002	46501
@NP	et al.	46501
@NP	2002	46509
@NP	None of the individual treatments	46516
@NP	None	46516
@NP	the individual treatments	46524
@NP	a significant improvement	46562
@NP	gross locomotor ability in the openfield -LRB- BBB score -RRB-	46591
@NP	gross locomotor ability	46591
@NP	the openfield -LRB- BBB score -RRB-	46618
@NP	the openfield	46618
@NP	BBB score	46633
@NP	injury-only controls	46656
@NP	the combination of MP/IL -10 with later SC/OEG grafting	46682
@NP	the combination	46682
@NP	MP/IL -10 with later SC/OEG grafting	46701
@NP	MP/IL -10	46701
@NP	later SC/OEG grafting	46715
@NP	a significant improvement in BBB score	46753
@NP	a significant improvement	46753
@NP	BBB score	46782
@NP	controls	46797
@NP	a reduction	46815
@NP	normal-appearing tissue observed with this combination compared to MP/IL10 alone	46830
@NP	normal-appearing tissue	46830
@NP	this combination	46868
@NP	MP/IL10 alone	46897
@NP	This	46912
@NP	the fact	46937
@NP	there	46951
@NP	no significant reduction in axon sparing between the two groups	46961
@NP	no significant reduction	46961
@NP	axon sparing between the two groups	46989
@NP	axon sparing	46989
@NP	the two groups	47010
@NP	retrograde tracing	47036
@NP	retrograde	47036
@NP	the reduction in normal tissue volume	47070
@NP	the reduction	47070
@NP	normal tissue volume	47087
@NP	gray matter	47129
@NP	little bearing on motor function	47159
@NP	little bearing	47159
@NP	motor function	47177
@NP	this spinal cord level	47195
@NP	The employment	47219
@NP	the recovery of features	47263
@NP	the recovery	47263
@NP	features	47279
@NP	the upper end of the BBB scale	47291
@NP	the upper end	47291
@NP	the BBB scale	47308
@NP	animals with SC/OEG grafts	47334
@NP	animals	47334
@NP	SC/OEG grafts	47347
@NP	significant improvement	47371
@NP	toe clearance	47398
@NP	correct tail position	47426
@NP	the other groups	47461
@NP	no additional benefit of MP/IL -10 administration	47496
@NP	no additional benefit	47496
@NP	MP/IL -10 administration	47521
@NP	Investigation	47562
@NP	fine motor performance using footprint analysis and gridwalk testing	47579
@NP	fine motor performance	47579
@NP	footprint analysis and gridwalk testing	47608
@NP	footprint analysis	47608
@NP	gridwalk testing	47631
@NP	a significant improvement , fewer footfall errors on a gridwalk ,	47661
@NP	a significant improvement	47661
@NP	fewer footfall errors on a gridwalk	47688
@NP	fewer footfall errors	47688
@NP	a gridwalk	47713
@NP	animals treated with MP/IL -10	47728
@NP	animals	47728
@NP	MP/IL -10	47749
@NP	The degree of behavioral recovery -LRB- as revealed by BBB scoring -RRB-	47759
@NP	The degree of behavioral recovery	47759
@NP	The degree	47759
@NP	behavioral recovery	47773
@NP	BBB scoring	47809
@NP	systemic administration	47827
@NP	IL-10 -LRB- and MP -RRB-	47854
@NP	IL-10	47854
@NP	that	47906
@NP	Bethea and colleagues -LRB- 1999 -RRB-	47923
@NP	Bethea	47923
@NP	colleagues -LRB- 1999 -RRB-	47934
@NP	colleagues	47934
@NP	1999	47946
@NP	a significant increase	47961
@NP	tissue sparing observed in both studies and the use of the same SCI model	47987
@NP	tissue sparing	47987
@NP	both studies and the use	48014
@NP	studies	48019
@NP	the use	48031
@NP	the same SCI model	48042
@NP	A possible explanation for this disparity	48062
@NP	A possible explanation	48062
@NP	this disparity	48089
@NP	the present study	48115
@NP	we	48133
@NP	Fischer rats , a more inbred strain	48141
@NP	Fischer rats	48141
@NP	a more inbred strain	48155
@NP	the Sprague-Dawley rat	48181
@NP	the other study -LRB- Bethea et al. , 1999 -RRB-	48223
@NP	the other study	48223
@NP	Bethea	48240
@NP	et al. , 1999	48247
@NP	et al.	48247
@NP	1999	48255
@NP	they	48270
@NP	Fischer rats	48287
@NP	transplantation studies	48322
@NP	our laboratory and others	48349
@NP	Weidner et al. , 1999 ; Thomas et al. , 2000 ; Bamber et al. , 2001	48376
@NP	Weidner	48376
@NP	et al. , 1999 ; Thomas et al. , 2000 ; Bamber et al. , 2001	48384
@NP	et al. , 1999	48384
@NP	et al.	48384
@NP	1999	48392
@NP	Thomas et al. , 2000	48398
@NP	Thomas	48398
@NP	et al. , 2000	48405
@NP	et al.	48405
@NP	2000	48413
@NP	Bamber et al. , 2001	48419
@NP	Bamber	48419
@NP	et al. , 2001	48426
@NP	et al.	48426
@NP	2001	48434
@NP	It	48441
@NP	certain inflammatory responses	48471
@NP	strain specific	48506
@NP	some strains	48531
@NP	Ôimmune privileged Õ whereas others are not	48548
@NP	Ôimmune privileged Õ	48548
@NP	others	48577
@NP	Popovich	48593
@NP	et al. , 1997 ; Sams et al. , 2000	48602
@NP	et al.	48602
@NP	1997 ; Sams et al.	48610
@NP	1997	48610
@NP	Sams et al.	48616
@NP	Sams	48616
@NP	et al.	48621
@NP	2000	48629
@NP	Animals receiving SC grafts	48636
@NP	Animals	48636
@NP	SC grafts	48654
@NP	a significant reduction	48679
@NP	the degree of foot exo-rotation	48706
@NP	the degree	48706
@NP	foot exo-rotation	48720
@NP	injured-only controls	48750
@NP	The combination of MP/IL -10 with cell transplantation	48773
@NP	The combination	48773
@NP	MP/IL -10 with cell transplantation	48792
@NP	MP/IL -10	48792
@NP	cell transplantation	48806
@NP	gridwalk and footprint results over the individual strategies	48855
@NP	gridwalk and footprint	48855
@NP	the individual strategies	48891
@NP	fact	48921
@NP	the combination of MP/IL -10 with SC grafting actually	48927
@NP	the combination	48927
@NP	MP/IL -10 with SC grafting actually	48946
@NP	MP/IL -10	48946
@NP	SC grafting actually	48960
@NP	SC	48960
@NP	motor performance compared to SC	48990
@NP	motor performance	48990
@NP	SC	49020
@NP	MP/IL -10-only animals ; there was a significantly greater base of support	49027
@NP	MP/IL -10-only animals	49027
@NP	there	49050
@NP	a significantly greater base of support	49060
@NP	a significantly greater base	49060
@NP	support	49092
@NP	less trunk stability	49101
@NP	a wider angle	49124
@NP	foot exo-rotation	49141
@NP	more numerous footfall errors on the gridwalk test	49164
@NP	more numerous footfall errors	49164
@NP	the gridwalk test	49197
@NP	The results	49216
@NP	previous studies	49251
@NP	MP	49291
@NP	the growth of fibers	49307
@NP	the growth	49307
@NP	fibers	49321
@NP	SC transplants -LRB- Chen et al. , 1996 -RRB-	49333
@NP	SC transplants	49333
@NP	Chen	49349
@NP	et al. , 1996	49354
@NP	et al.	49354
@NP	1996	49362
@NP	combination with OEG grafts -LRB- Nash et al. , 2002 -RRB-	49376
@NP	combination	49376
@NP	OEG grafts -LRB- Nash et al. , 2002 -RRB-	49393
@NP	OEG grafts	49393
@NP	Nash	49405
@NP	et al. , 2002	49410
@NP	et al.	49410
@NP	2002	49418
@NP	regeneration and behavioral recovery	49437
@NP	regeneration	49437
@NP	behavioral recovery	49454
@NP	conclusion	50050
@NP	it	50062
@NP	SCI either tissue sparing interventions	50085
@NP	SCI	50085
@NP	tissue sparing interventions	50096
@NP	tissue loss and the accompanying behavioral deficits	50136
@NP	tissue loss	50136
@NP	the accompanying behavioral deficits	50152
@NP	cell transplantation strategies	50193
@NP	the injured spinal cord	50259
@NP	function	50294
@NP	important roles in recovery	50314
@NP	important roles	50314
@NP	recovery	50333
@NP	SCI	50347
@NP	We	50352
@NP	a protective regimen -LRB- MP/IL -10 -RRB-	50378
@NP	a protective regimen	50378
@NP	MP/IL -10	50400
@NP	cell transplantation -LRB- SC and SC/OEG grafts -RRB-	50414
@NP	cell transplantation	50414
@NP	SC and SC/OEG grafts	50436
@NP	SC	50436
@NP	SC/OEG grafts	50443
@NP	we	50458
@NP	significant improvements	50473
@NP	behavioral recovery over injured-only controls	50501
@NP	behavioral recovery	50501
@NP	injured-only controls	50526
@NP	the individual treatments	50568
@NP	We	50601
@NP	cell grafting subsequent to a protective regimen	50619
@NP	cell grafting	50619
@NP	a protective regimen	50647
@NP	normal-appearing tissue volume compared to the protective regimen	50679
@NP	normal-appearing tissue volume	50679
@NP	the protective regimen	50722
@NP	a need	50761
@NP	re-administration of the protective agents at the time of cell grafting	50779
@NP	re-administration	50779
@NP	the protective agents at the time of cell grafting	50800
@NP	the protective agents	50800
@NP	the time of cell grafting	50825
@NP	the time	50825
@NP	cell grafting	50837
@NP	a less invasive transplantation procedure	50854
@NP	we	50911
@NP	a combination of MP/IL -10 and SC grafts-only	50931
@NP	a combination	50931
@NP	MP/IL -10 and SC grafts-only	50948
@NP	MP/IL -10	50948
@NP	SC grafts-only	50961
@NP	behavioral restitution	51001
@NP	both the individual treatments and injured-only controls	51029
@NP	the individual treatments	51034
@NP	injured-only controls	51064
@NP	The current study	51087
@NP	the importance	51116
@NP	administered protective agents	51152
@NP	the milieu of the injured spinal cord for transplanted cells	51194
@NP	the milieu	51194
@NP	the injured spinal cord for transplanted cells	51208
@NP	the injured spinal cord	51208
@NP	transplanted cells	51236
@NP	they	51262
@NP	the function of these cells	51286
@NP	the function	51286
@NP	these cells	51302
@VP	Enhance Recovery	152
@VP	are tissue protective acutely after spinal cord injury -LRB- SCI -RRB-	367
@VP	offers additive protection -LRB- Takami et al. , 2002a -RRB-	447
@VP	transplanted into rat thoracic cord 1 week after contusive injury	746
@VP	tracing	878
@VP	encompassing the injury site at 12 weeks	1104
@VP	most significantly reduced cavitation	1215
@VP	seen when MP/IL -10 and cell grafts were combined compared to MP/IL -10 alone	1457
@VP	were combined compared to MP/IL -10 alone	1492
@VP	combined compared to MP/IL -10 alone	1497
@VP	were effective in promoting serotonergic fiber growth into the graft	1548
@VP	promoting serotonergic fiber growth into the graft	1566
@VP	led to more reticulospinal fibers caudal to the graft	1621
@VP	caudal to the graft	1655
@VP	did not further increase fiber number	1702
@VP	given prior to SC-only transplants	1899
@VP	worsened behavioral outcome	1944
@VP	were not always additive when combined with cell transplantation	2012
@VP	combined with cell transplantation	2042
@VP	employed to reduce damage to tissue spared by an earlier protection strategy	2374
@VP	to reduce damage to tissue spared by an earlier protection strategy	2383
@VP	reduce damage to tissue spared by an earlier protection strategy	2386
@VP	spared by an earlier protection strategy	2410
@VP	TO	2473
@VP	aimed at replacing missing tissue and restoring lost connections and function	2983
@VP	replacing missing tissue and restoring lost connections and function	2992
@VP	replacing missing tissue	2992
@VP	missing tissue	3002
@VP	restoring lost connections and function	3021
@VP	recommended for use acutely following SCI in the United States	3196
@VP	is protective	3451
@VP	is still an open question	3465
@VP	significantly reduce tissue loss	4161
@VP	improve open-field locomotion -LRB- Bethea et al. , 1999 -RRB-	4198
@VP	combining both MP and IL-10 after spinal cord contusion	4285
@VP	administered alone	4414
@VP	retards injury-induced tissue damage after SCI	4595
@VP	functional deficits persist -LRB- Takami et al. , 2002a -RRB-	4650
@VP	persist	4670
@VP	to achieve functional restitution	4711
@VP	achieve functional restitution	4714
@VP	replace lost cells	4795
@VP	grafting into the injured spinal cord	5535
@VP	implanted into the host spinal cord stumps after complete transection	5979
@VP	descending	6079
@VP	ascending axons into the caudal and rostral cord , respectively	6094
@VP	mirrors a common form of human SCI	6412
@VP	described previously	6631
@VP	inactivated fetal bovine serum -LRB- FBS -RRB- without mitogens	6756
@VP	were enzymatically dissociated	6923
@VP	enzymatically dissociated	6928
@VP	were grown to confluency and passaged to new dishes three times	7201
@VP	grown to confluency and passaged to new dishes three times	7206
@VP	grown to confluency	7206
@VP	passaged to new dishes three times	7230
@VP	described earlier -LRB- Takami et al. , 2002b -RRB-	7305
@VP	was found to be 95-98 %	7347
@VP	found to be 95-98 %	7351
@VP	to be 95-98 %	7357
@VP	be 95-98 %	7360
@VP	purified cultures of OEG	7406
@VP	were prepared from the nerve fiber	7431
@VP	prepared from the nerve fiber	7436
@VP	modified from one described previously	7553
@VP	described previously	7571
@VP	was taken to minimize the inclusion of non-nerve fiber layer bulb tissue	7625
@VP	taken to minimize the inclusion of non-nerve fiber layer bulb tissue	7629
@VP	to minimize the inclusion of non-nerve fiber layer bulb tissue	7635
@VP	minimize the inclusion of non-nerve fiber layer bulb tissue	7638
@VP	was removed	7711
@VP	removed	7715
@VP	were dissociated	7728
@VP	dissociated	7733
@VP	described by Takami et al. -LRB- 2002b -RRB-	7941
@VP	preceded harvesting at confluency for transplantation	8005
@VP	harvesting at confluency for transplantation	8014
@VP	Checking the purity was similar to SCs except that p75 rather than S100	8060
@VP	was similar to SCs except that p75 rather than S100	8080
@VP	was used with Hoechst nuclear staining	8132
@VP	used with Hoechst nuclear staining	8136
@VP	was found to be 94-98 %	8179
@VP	found to be 94-98 %	8183
@VP	to be 94-98 %	8189
@VP	be 94-98 %	8192
@VP	were housed according to NIH and USDA guidelines	8269
@VP	housed according to NIH and USDA guidelines	8274
@VP	approved all animal procedures	8394
@VP	was shaved and aseptically prepared with betadine	8672
@VP	shaved	8676
@VP	to prevent drying	8816
@VP	prevent drying	8819
@VP	drying	8827
@VP	administered intramuscularly	8926
@VP	were kept on a heating pad to maintain the body temperature at 37 ± 0.5 °C	8981
@VP	kept on a heating pad to maintain the body temperature at 37 ± 0.5 °C	8986
@VP	to maintain the body temperature at 37 ± 0.5 °C	9008
@VP	maintain the body temperature at 37 ± 0.5 °C	9011
@VP	was induced by the weight drop device	9091
@VP	induced by the weight drop device	9095
@VP	developed at New	9129
@VP	was made along the thoracic vertebra and the superficial muscle	9220
@VP	made along the thoracic vertebra and the superficial muscle	9224
@VP	retracted	9293
@VP	performed at thoracic vertebra T8	9318
@VP	disrupting the dura mater	9422
@VP	placed around the vertebrae at T6 and T12 to support the column during impact	9475
@VP	to support the column during impact	9517
@VP	support the column during impact	9520
@VP	was moderately injured by dropping a 10.0-g rod from a height of 12.5 mm	9578
@VP	dropping a 10.0-g rod from a height of 12.5 mm	9604
@VP	were monitored	9706
@VP	monitored	9711
@VP	exceeded 6 %	9795
@VP	was not within the range of 1.35-1.75 mm	9838
@VP	were sutured in layers	9906
@VP	sutured in layers	9911
@VP	closed with metal wound clips	9942
@VP	were allowed to recover in a warmed cage with water and food easily accessible	9982
@VP	allowed to recover in a warmed cage with water and food easily accessible	9987
@VP	to recover in a warmed cage with water and food easily accessible	9995
@VP	recover in a warmed cage with water and food easily accessible	9998
@VP	was administered 2 , 4 , and 6 days after injury	10080
@VP	administered 2 , 4 , and 6 days after injury	10084
@VP	were maintained for 12 weeks after injury	10137
@VP	maintained for 12 weeks after injury	10142
@VP	made in the right ventral neck region before injury to expose the jugular vein	10349
@VP	to expose the jugular vein	10401
@VP	expose the jugular vein	10404
@VP	filled with saline	10499
@VP	was then inserted 3-5 mm into the vein and stabilized with 7-0 silk sutures	10518
@VP	was then inserted 3-5 mm into the vein	10518
@VP	inserted 3-5 mm into the vein	10527
@VP	stabilized with 7-0 silk sutures	10561
@VP	was administered intravenously -LRB- i.v. -RRB-	10825
@VP	administered intravenously -LRB- i.v. -RRB-	10829
@VP	were returned to their cages to recover	10892
@VP	returned to their cages to recover	10897
@VP	to recover	10921
@VP	recover	10924
@VP	was then readministered by catheter at 2 and 4 hours post-injury	10936
@VP	then readministered by catheter at 2	10940
@VP	Shering	11055
@VP	grafted -LRB- n = 14 -RRB-	11444
@VP	grafted	11476
@VP	grafted -LRB- n = 13 -RRB-	11501
@VP	grafted -LRB- n = 14 -RRB-	11537
@VP	tracing and five for volume analysis and immunochemistry	11639
@VP	received 8 weeks of behavioral testing	11965
@VP	were injected with 6 µL of DMEM-F12 medium	12448
@VP	injected with 6 µL of DMEM-F12 medium	12453
@VP	were performed over a 3-minute period	12507
@VP	performed over a 3-minute period	12512
@VP	kept in place for an additional 3 minutes to minimize leakage upon withdrawal	12576
@VP	to minimize leakage upon withdrawal	12618
@VP	minimize leakage upon withdrawal	12621
@VP	were closed separately	12708
@VP	closed separately	12713
@VP	tracing	12775
@VP	tracing	12800
@VP	were reanesthetized with 2 % halothane	12834
@VP	reanesthetized with 2 % halothane	12839
@VP	biotinylated dextran amine	12881
@VP	injected stereotaxically	12948
@VP	bilaterally into the hindlimb area of the motor cortex -LRB- 2 x 0.5 µL -RRB-	12977
@VP	to ensure accurate tracer injection into all three areas in each animal	13304
@VP	ensure accurate tracer injection into all three areas in each animal	13307
@VP	tracing	13401
@VP	were re-anesthetized with 2 % halothane	13437
@VP	re-anesthetized with 2 % halothane	13442
@VP	held in a micromanipulator -LRB- Takami et al. , 2002b -RRB-	13737
@VP	were performed over a 3-minute period	13803
@VP	performed over a 3-minute period	13808
@VP	kept in place for an additional 3 minutes to minimize leakage upon withdrawal	13872
@VP	to minimize leakage upon withdrawal	13914
@VP	minimize leakage upon withdrawal	13917
@VP	were closed in layers	13993
@VP	closed in layers	13998
@VP	contained the complete lesion	14330
@VP	to prevent further damage during histological procedures	14510
@VP	prevent further damage during histological procedures	14513
@VP	cut into 30 µm thick sagittal sections and used to examine anterograde tracing	14604
@VP	cut into 30 µm thick sagittal sections	14604
@VP	used to examine anterograde tracing	14647
@VP	to examine anterograde tracing	14652
@VP	examine anterograde tracing	14655
@VP	tracing	14675
@VP	collected in PBS -LRB- 0.1 M , pH 7.4 -RRB-	14698
@VP	stored at 4 ¡ C until further processing	14735
@VP	can reduce the intensity of this fluorescence	14876
@VP	reduce the intensity of this fluorescence	14880
@VP	mounted onto gelatin-coated slides	15138
@VP	cut into 10-µm-thick sagittal sections	15300
@VP	used to examine histological and immunohistochemical staining	15343
@VP	to examine histological and immunohistochemical staining	15348
@VP	examine histological and immunohistochemical staining	15351
@VP	allowed better study of damaged vs normal-appearing tissue after staining	15429
@VP	damaged vs normal-appearing tissue after staining	15453
@VP	stained with haematoxylin , eosin and luxol fast blue , dehydrated	15721
@VP	using an image analysis computer system	15915
@VP	was first determined	16090
@VP	first determined	16094
@VP	were determined	16156
@VP	determined	16161
@VP	Damaged tissue	16173
@VP	summed per rat	16386
@VP	was analyzed	16447
@VP	analyzed	16451
@VP	cavitated and damaged spinal tissue	16535
@VP	included cavity , damaged and normal-appearing tissue volumes	16800
@VP	processed similarly to determine the mean volume of the normal T8Ð10 spinal cord	17075
@VP	to determine the mean volume of the normal T8Ð10 spinal cord	17095
@VP	determine the mean volume of the normal T8Ð10 spinal cord	17098
@VP	BDA - , DFl - , or DRh-labeled axons were	17199
@VP	BDA	17199
@VP	, DFl - , or DRh-labeled axons were	17203
@VP	DFl - , or DRh-labeled axons were	17205
@VP	, or DRh-labeled axons were	17209
@VP	spanning the width of the spinal cord	17326
@VP	BDAlabeled	17366
@VP	were detected using fluorescence microscopy	17515
@VP	detected using fluorescence microscopy	17520
@VP	using fluorescence microscopy	17529
@VP	summed per rat and multiplied by 4 to obtain the final number of labeled axons	17863
@VP	summed per rat	17863
@VP	multiplied by 4 to obtain the final number of labeled axons	17882
@VP	to obtain the final number of labeled axons	17898
@VP	obtain the final number of labeled axons	17901
@VP	To assess numbers of neurons labeled by retrograde tracing	17943
@VP	assess numbers of neurons labeled by retrograde tracing	17946
@VP	labeled by retrograde tracing	17972
@VP	tracing	17994
@VP	was first identified according to the rat brain atlas -LRB- Paxinos , 1998 -RRB-	18023
@VP	identified according to the rat brain atlas -LRB- Paxinos , 1998 -RRB-	18033
@VP	counted in the sensorimotor cortex , reticular formation and vestibular nuclei	18130
@VP	were summed	18223
@VP	summed	18228
@VP	calculated for each region according to the following formula	18287
@VP	labeled neuron sum/number of sections analyzed for the region	18402
@VP	analyzed for the region	18440
@VP	obtain the final summed number of labeled neurons for each region in each animal	18470
@VP	described	18722
@VP	used	18791
@VP	used	18964
@VP	used	19114
@VP	mounted onto gelatin-coated glass slides	19276
@VP	coverslipped in Vectorshield mounting medium	19321
@VP	mounting medium	19350
@VP	to identify the transplant	19763
@VP	identify the transplant	19766
@VP	were then counted and summed per rat	19872
@VP	counted and summed per rat	19882
@VP	To estimate the number of fibers per section	19910
@VP	estimate the number of fibers per section	19913
@VP	were then divided by the number of sections examined	19967
@VP	divided by the number of sections examined	19977
@VP	examined	20011
@VP	taken of 2-mm-wide areas of the spinal cord rostral to	20124
@VP	was used as a marker for astrogliosis	20374
@VP	used as a marker for astrogliosis	20378
@VP	automatically measured	20557
@VP	gave in arbitrary	20585
@VP	to give a mean GFAP intensity both rostral and caudal per animal	20727
@VP	give a mean GFAP intensity both rostral and caudal per animal	20730
@VP	developed by Basso et al. -LRB- 1995 , 1996 -RRB-	20915
@VP	performed the test once a week for 8 weeks	21010
@VP	follow the progression of the BBB score -LRB- Popovich et al. , 1999 -RRB-	21151
@VP	Walk Test	21221
@VP	described previously by Metz et al. -LRB- 2000 -RRB-	21414
@VP	Crossing this runway	21458
@VP	requires that animals accurately place their limbs on the bars	21479
@VP	place their limbs on the bars	21512
@VP	had to cross the grid at least three times	21604
@VP	to cross the grid at least three times	21608
@VP	cross the grid at least three times	21611
@VP	was counted in each crossing	21681
@VP	counted in each crossing	21685
@VP	crossing	21701
@VP	was calculated	21732
@VP	calculated	21736
@VP	using a protocol modified from de Medinaceli et al. -LRB- 1982 -RRB-	21812
@VP	modified from de Medinaceli et al. -LRB- 1982 -RRB-	21829
@VP	were inked	21895
@VP	inked	21900
@VP	were made on paper covering a narrow runway of 1 m in length and 7 cm in width	21921
@VP	made on paper covering a narrow runway of 1 m in length and 7 cm in width	21926
@VP	covering a narrow runway of 1 m in length and 7 cm in width	21940
@VP	ensured that the direction of each step was standardized in line	22006
@VP	was standardized in line	22046
@VP	measuring the core-to-core distance of the central pads of the hind paws	22266
@VP	was measured between the central pads of two consecutive prints on each side	22545
@VP	measured between the central pads of two consecutive prints on each side	22549
@VP	followed by FisherÕs	22658
@VP	comparing results of the tissue volume analysis , retrograde neuronal tracing	22743
@VP	tracing	22812
@VP	repeated ANOVA followed by the Tukey-Kramer test	22928
@VP	followed by the Tukey-Kramer test	22943
@VP	was used for comparison of weekly functional recovery patterns after injury	22977
@VP	used for comparison of weekly functional recovery patterns after injury	22981
@VP	to be statistically significant at p < 0.05 * , ,0.01 ** , and ,0.001 ***	23080
@VP	be statistically significant at p < 0.05 * , ,0.01 ** , and ,0.001 ***	23083
@VP	0.05 * , ,0.01 **	23119
@VP	are given as standard deviations	23161
@VP	given as standard deviations	23165
@VP	TABLE 1	23204
@VP	ENCOMPASSING THE INJURY TABLE 2	23270
@VP	reduces cavitation	23420
@VP	is in the middle of the 9-mm-long segment of spinal cord	23617
@VP	= 1 mm	23794
@VP	increases total cord volume and normal-appearing tissue volume	23844
@VP	decreases cavitation	23911
@VP	showing the border between normal-appearing tissue and damaged / grafted tissue	23991
@VP	showing the border between normal-appearing tissue	23991
@VP	damaged / grafted tissue	24046
@VP	grafted tissue	24055
@VP	delineated by white arrows	24071
@VP	= 50 µm	24219
@VP	encompassing the injury site at its center	24290
@VP	expressed as a percentage of total cord volume	24387
@VP	are found only in SC/OEG grafts	24966
@VP	found only in SC/OEG grafts	24970
@VP	do not increase with MP/IL -10	25016
@VP	increase with MP/IL -10	25023
@VP	traced fibers/section 2500 µm rostral to , within ,	25075
@VP	to	25113
@VP	was delineated by p75 immunoreactivity	25288
@VP	delineated by p75 immunoreactivity	25292
@VP	are present only within SC/OEG grafts	25462
@VP	showing the three perpendicular lines rostral to , at the center of	25513
@VP	crossing 5HT1 fibers	25614
@VP	were recorded	25635
@VP	recorded	25640
@VP	was delineated by p75 immunoreactivity	25805
@VP	delineated by p75 immunoreactivity	25809
@VP	caudal to the injury/transplant site	26076
@VP	reduces gliosis after injury	26755
@VP	exhibit significantly less host cord gliosis than SC grafts	26799
@VP	were photographed to measure GFAP intensity	26999
@VP	photographed to measure GFAP intensity	27004
@VP	to measure GFAP intensity	27017
@VP	measure GFAP intensity	27020
@VP	leads to early and persistent gross behavioral improvement	27447
@VP	was assessed weekly using the BBB score at 1Ð8 weeks post-transplantation	27540
@VP	assessed weekly using the BBB score at 1Ð8 weeks post-transplantation	27544
@VP	using the BBB score at 1Ð8 weeks post-transplantation	27560
@VP	compared to injury-only controls	27948
@VP	improves fine locomotor performance at 8 weeks	28037
@VP	worsens outcome	28121
@VP	permeated by numerous small cells , most likely infiltrating immune cells	28943
@VP	infiltrating immune cells	28990
@VP	Surrounding damaged tissue rostrally	29017
@VP	reduced tissue cavitation -LRB- Fig. 1B -RRB-	29233
@VP	receiving either SC or SC/OEG grafts	29281
@VP	did not contain neurons	29514
@VP	contain neurons	29522
@VP	exhibited high numbers of small cells -LRB- transplanted or immune cells -RRB-	29542
@VP	distinguished from damaged tissue without immunostaining -LRB- see below -RRB-	29628
@VP	see below	29686
@VP	delineated from normal-appearing spinal tissue which contained neurons	29726
@VP	contained neurons	29779
@VP	exhibited normal cellular density -LRB- Fig. 2A -RRB-	29819
@VP	were evaluated	29943
@VP	evaluated	29948
@VP	was 28.2 ± 1.2 mm3	30033
@VP	was observed	30142
@VP	observed	30146
@VP	were 15.4 ± 1.5 and 6.0 ± 0.7 mm3 , respectively -LRB- Table 1 , Fig. 2B -RRB-	30218
@VP	was 54.7 ± 5.3 %	30434
@VP	was 38.8 ± 2.7 % -LRB- Fig. 2C -RRB-	30516
@VP	received MP/IL -10 or SC transplants	30563
@VP	reduced the volume of cavitation -LRB- p < 0.05 -RRB-	30800
@VP	grafting further	31027
@VP	reduced cavitation -LRB- p < 0.05 -RRB-	31044
@VP	damaged tissue	31124
@VP	exhibited increased cellular density , myelin disruption	31158
@VP	containing neurons	31284
@VP	damaged	31645
@VP	could not be discriminated from the graft	31660
@VP	be discriminated from the graft	31670
@VP	discriminated from the graft	31673
@VP	are not reported	31744
@VP	reported	31752
@VP	did not contain neurons or typical cellular density	31855
@VP	contain neurons or typical cellular density	31863
@VP	received MP/IL -10	32111
@VP	tracing to examine the presence of brainstem axons	32623
@VP	to examine the presence of brainstem axons	32631
@VP	examine the presence of brainstem axons	32634
@VP	found within grafts even with precedent MP/IL -10 -LRB- Fig. 3A , C -RRB-	32788
@VP	traced vestibulospinal fibers	32864
@VP	were observed in preserved white matter around the injury/graft site	32894
@VP	observed in preserved white matter around the injury/graft site	32899
@VP	were present rostral to the grafted area	32989
@VP	grafted groups	33123
@VP	extended only small sprouts across the rostral graft/host interface	33164
@VP	grafts	33244
@VP	sprouting of reticulospinal fibers	33260
@VP	was seen	33295
@VP	seen	33299
@VP	grafted animals -LRB- three of five -RRB-	33327
@VP	could be seen to reach the center of the graft and an occasional fiber	33425
@VP	be seen to reach the center of the graft and an occasional fiber	33431
@VP	seen to reach the center of the graft and an occasional fiber	33434
@VP	to reach the center of the graft and an occasional fiber	33439
@VP	reach the center of the graft and an occasional fiber	33442
@VP	exited the graft for a short distance into the caudal spinal cord	33496
@VP	grafted groups	33577
@VP	were present in both white and gray matter rostral to the graft site	33804
@VP	entering the grafts when MP/IL -10 was also administered -LRB- Fig. 4A , B -RRB-	34016
@VP	was also administered -LRB- Fig. 4A , B -RRB-	34050
@VP	administered -LRB- Fig. 4A , B -RRB-	34059
@VP	Labeled neurons in the motor cortex	34291
@VP	were quantified -LRB- Fig. 5DÐF -RRB-	34371
@VP	quantified -LRB- Fig. 5DÐF -RRB-	34376
@VP	injured controls	34415
@VP	were 9.0 ± 3.8 , 3280 ± 560 , and 4370 ± 740 , respectively	34543
@VP	labeled neurons in the motor cortex	34640
@VP	was observed in all treatment groups -LRB- Fig. 5D-F -RRB-	34698
@VP	observed in all treatment groups -LRB- Fig. 5D-F -RRB-	34702
@VP	increased sparing	34793
@VP	sparing	34803
@VP	did not improve reticulospinal fiber sparing/regeneration	35057
@VP	improve reticulospinal fiber sparing/regeneration	35065
@VP	assessing the intensity of GFAP immunoreactivity	35273
@VP	measured in arbitrary units	35426
@VP	was 85.65 ± 14.32 and 110.27 ± 11.69 , respectively -LRB- Fig. 6B -RRB-	35455
@VP	was present around the injury site and within tissue bridges	35539
@VP	following MP/IL -10 administration alone	35731
@VP	caudally -LRB- 192.34 ± 19.09 ; p < 0.01 -RRB- compared to injury-only controls	35893
@VP	surrounding the graft/injury site	36046
@VP	were found within the grafts	36105
@VP	found within the grafts	36110
@VP	was not similarly increased -LRB- Fig. 6B -RRB-	36210
@VP	increased -LRB- Fig. 6B -RRB-	36228
@VP	reached a plateau over the next 5-6 weeks -LRB- Fig. 7A -RRB-	36521
@VP	received no treatment after contusion	36592
@VP	exhibited occasional to frequent weight-supported plantar steps	36683
@VP	controls	36850
@VP	was seen only with the combination of SC/OEG grafting and acute MP/IL -10	36918
@VP	seen only with the combination of SC/OEG grafting and acute MP/IL -10	36922
@VP	stepping with occasional to frequent coordination	37035
@VP	allowed us to examine the presence of certain features above score 14Ñe	37151
@VP	to examine the presence of certain features above score 14Ñe	37162
@VP	examine the presence of certain features above score 14Ñe	37165
@VP	scored on a 0-13-point scale	37341
@VP	controls	37384
@VP	exhibited a BBB subscore of 3 ± 1.9 at 8 weeks -LRB- Fig. 7B -RRB-	37393
@VP	showed significantly higher BBB subscores	37527
@VP	was seen between SC/OEG-only and SC/OEG 1 MP/IL -10 groups	37792
@VP	seen between SC/OEG-only and SC/OEG 1 MP/IL -10 groups	37796
@VP	was performed at 8 weeks	37887
@VP	performed at 8 weeks	37891
@VP	increased to a mean of 30.4 ± 2.3 °	38048
@VP	received SCs	38100
@VP	was significantly reduced , 25.7 ±	38132
@VP	reduced , 25.7 ±	38150
@VP	significantly abrogated this benefit -LRB- p < 0.001 -RRB-	38252
@VP	determined as the distance between the left and right hind paw central pads	38431
@VP	was not improved with any treatment	38508
@VP	improved with any treatment	38516
@VP	significantly worsened the base of support	38598
@VP	did not significantly change after injury -LRB- Fig. 8C -RRB-	38769
@VP	change after injury -LRB- Fig. 8C -RRB-	38791
@VP	spaced bars was assessed by counting the number of footfall errors	38864
@VP	was assessed by counting the number of footfall errors	38876
@VP	assessed by counting the number of footfall errors	38880
@VP	counting the number of footfall errors	38892
@VP	missed bars	38932
@VP	made by each hindlimb	38945
@VP	exhibited a mean error rate of 15.1 ± 1.5 -LRB- Fig. 8D -RRB-	39080
@VP	were not as effective in increasing normal-appearing tissue as MP/IL -10 alone	39872
@VP	increasing normal-appearing tissue as MP/IL -10 alone	39897
@VP	resulted in a significant improvement in gross locomotor performance	40003
@VP	improved the BBB score over injury-only controls	40145
@VP	-10 addition prior to SC-only transplants actually worsened behavioral outcome	40204
@VP	was observed with individual treatments	40336
@VP	observed with individual treatments	40340
@VP	is presented in Table 2	40405
@VP	presented in Table 2	40408
@VP	reduced cavitation	40508
@VP	differed significantly between treatment strategies	40944
@VP	receiving MP/IL -10	41005
@VP	target	41301
@VP	was given at a time when considerable secondary tissue loss had already occurred	41439
@VP	given at a time when considerable secondary tissue loss had already occurred	41443
@VP	had already occurred	41499
@VP	occurred	41511
@VP	antagonizing the acute inflammatory response after SCI	41571
@VP	maintains aerobic energy metabolism -LRB- Braughler and Hall , 1983 ; 1984 -RRB-	41807
@VP	would be expected to protect tissue during the acute phase of the injury	41959
@VP	be expected to protect tissue during the acute phase of the injury	41965
@VP	expected to protect tissue during the acute phase of the injury	41968
@VP	to protect tissue during the acute phase of the injury	41977
@VP	protect tissue during the acute phase of the injury	41980
@VP	mediated by SC or OEG grafts	42064
@VP	may not only promote axonal regeneration	42148
@VP	promote axonal regeneration	42161
@VP	provide trophic support to	42198
@VP	thus permit survival of the injured host cells	42229
@VP	to support neuronal survival	42345
@VP	support neuronal survival	42348
@VP	produced by OEG -LRB- Boruch et al. , 2001 ; Woodhall et al. , 2001 -RRB-	42676
@VP	filling lost tissue volume	42808
@VP	sparing intervention and later cellular grafting	43032
@VP	be expected to further enhance tissue preservation over either treatment alone	43085
@VP	expected to further enhance tissue preservation over either treatment alone	43088
@VP	to further enhance tissue preservation over either treatment alone	43097
@VP	further enhance tissue preservation over either treatment alone	43100
@VP	was observed with either combination over the individual strategies	43236
@VP	observed with either combination over the individual strategies	43240
@VP	reduced the volume of normal-appearing tissue compared to MP/IL10 alone	43355
@VP	examined in the current study or in the transplantation field in general	43709
@VP	would induce an inflammatory response	43874
@VP	induce an inflammatory response	43880
@VP	could in turn	43994
@VP	facilitate tissue damage	44008
@VP	associated with the cell transplantation procedure	44072
@VP	done previously by others -LRB- Chen et al. , 1996 ; Nash et al. , 2002 -RRB-	44200
@VP	introducing a retrograde tracer caudal to the injury/transplant site	44319
@VP	possessed fibers beyond the injury/transplant site	44451
@VP	were able to take up the tracer	44511
@VP	to take up the tracer	44521
@VP	take up the tracer	44524
@VP	was observed in all treatments compared to injured-only controls	44630
@VP	observed in all treatments compared to injured-only controls	44634
@VP	seen with the combination of MP/IL -10 with either cell transplantation paradigm	45166
@VP	to grow across SC or SC/OEG grafts	45382
@VP	grow across SC or SC/OEG grafts	45385
@VP	entered SC/OEG grafts	45445
@VP	were observed in SC grafts	45477
@VP	observed in SC grafts	45482
@VP	was unchanged by an earlier protective treatment with MP/IL -10	45522
@VP	reduce dieback of vestibulospinal axons -LRB- Oudega et al. , 1999 -RRB-	45627
@VP	grafted with OEG -LRB- Nash et al. , 2002 -RRB-	45773
@VP	completely transected rat spinal cord -LRB- Chen et al. , 1996 -RRB-	45878
@VP	has yet been demonstrated	45978
@VP	been demonstrated	45986
@VP	demonstrated	45991
@VP	abated the increase in astrogliosis seen in response to SC-only grafting	46172
@VP	seen in response to SC-only grafting	46208
@VP	observed with this combination compared to MP/IL10 alone	46854
@VP	tracing	47047
@VP	may be restricted to gray matter	47108
@VP	be restricted to gray matter	47112
@VP	may have little bearing on motor function at this spinal cord level	47150
@VP	have little bearing on motor function at this spinal cord level	47154
@VP	to examine the recovery of features at the upper end of the BBB scale	47252
@VP	examine the recovery of features at the upper end of the BBB scale	47255
@VP	displayed significant improvement in toe clearance	47361
@VP	exhibited correct tail position	47416
@VP	demonstrated no additional benefit of MP/IL -10 administration before grafting	47483
@VP	grafting	47552
@VP	using footprint analysis and gridwalk testing	47602
@VP	treated with MP/IL -10	47736
@VP	revealed by BBB scoring	47797
@VP	observed in both studies and the use of the same SCI model	48002
@VP	was used in the other study -LRB- Bethea et al. , 1999 -RRB-	48211
@VP	used in the other study -LRB- Bethea et al. , 1999 -RRB-	48215
@VP	are inbred	48275
@VP	are strain specific	48502
@VP	are not	48584
@VP	receiving SC grafts	48644
@VP	failed to improve gridwalk and footprint results over the individual strategies	48837
@VP	to improve gridwalk and footprint results over the individual strategies	48844
@VP	improve gridwalk and footprint results over the individual strategies	48847
@VP	results over the individual strategies	48878
@VP	grafting actually	48963
@VP	was a significantly greater base of support	49056
@VP	increase the growth of fibers into SC transplants -LRB- Chen et al. , 1996 -RRB-	49298
@VP	can promote regeneration and behavioral recovery	49425
@VP	promote regeneration and behavioral recovery	49429
@VP	to replace , repair and reconnect the injured spinal cord to restore function	50226
@VP	replace , repair and reconnect the injured spinal cord to restore function	50229
@VP	to restore function	50283
@VP	restore function	50286
@VP	will play important roles in recovery from SCI	50304
@VP	play important roles in recovery from SCI	50309
@VP	will alter the milieu of the injured spinal cord for transplanted cells	51183
@VP	alter the milieu of the injured spinal cord for transplanted cells	51188
@VP	may interfere with the function of these cells	51267
@VP	interfere with the function of these cells	51271
